

The Growth Fund of America®

Financial Statements and Other Information N-CSR Items 7-11

for the year ended August 31, 2024

Investment portfolio August 31, 2024

Common stoc	ks 96.21%	Shares	Valu (000
Information	Microsoft Corp.	40,020,432	\$16,694,123
technology	NVIDIA Corp.	82,393,553	9,835,318
25.75%	Broadcom, Inc.	56,400,187	9,183,078
	Apple, Inc.	29,887,753	6,844,29
	Taiwan Semiconductor Manufacturing Co., Ltd.	113,386,000	3,385,619
	Taiwan Semiconductor Manufacturing Co., Ltd. (ADR)	4,097,537	703,547
	Salesforce, Inc.	13,679,966	3,459,663
	ASML Holding NV	1,521,734	1,376,30
	ASML Holding NV (ADR)	1,474,325	1,332,598
	Shopify, Inc., Class A, subordinate voting shares ¹	30,336,478	2,247,023
	ServiceNow, Inc. ¹	1,983,706	1,696,069
	Applied Materials, Inc.	8,479,153	1,672,598
	Cloudflare, Inc., Class A ¹	19,520,442	1,603,409
	Synopsys, Inc. ¹	2,636,937	1,370,100
	Motorola Solutions, Inc.	2,926,280	1,293,533
	Texas Instruments, Inc.	5,986,964	1,283,24
	MicroStrategy, Inc., Class A ^{1,2}	8,240,520	1,091,210
	Constellation Software, Inc.	313,009	1,022,11
	Arista Networks, Inc. ¹	2,778,678	981,929
	Micron Technology, Inc.	7,435,007	715,54
	Palo Alto Networks, Inc. ¹	1,336,353	484,722
	Dell Technologies, Inc., Class C	4,060,926	469,199
	Adobe, Inc. ¹	719,337	413,194
	Atlassian Corp., Class A ¹	2,396,791	396,909
	SAP SE	1,439,426	313,949
	MongoDB, Inc., Class A ¹	1,024,648	297,95
	Unity Software, Inc. ¹	17,523,088	286,853
	Monolithic Power Systems, Inc.	299,079	279,543
	Oracle Corp.	1,765,128	249,39
	Datadog, Inc., Class A ¹	2,071,890	240,878
	Roper Technologies, Inc.	343,482	190,430
	DocuSign, Inc. ¹	3,215,944	190,41
	NICE, Ltd. (ADR) ¹	1,007,117	174,97
	Aurora Innovation, Inc., Class A ¹	34,242,700	159,913
	ASM International NV	210,463	143,347
	EPAM Systems, Inc. ¹	640,236	128,534
	Fair Isaac Corp. ¹	73,697	127,51
	First Solar, Inc. ¹	540,682	122,93
	Flex, Ltd. ¹	3,715,000	120,700
	Elastic NV, non-registered shares ¹	1,393,386	106,162
	RingCentral, Inc., Class A ¹	2,998,917	99,954
	Accenture PLC, Class A	254,711	87,098
	Autodesk, Inc. ¹	307,643	79,49
	Snowflake, Inc., Class A ¹	635,529	72,59
	Wolfspeed, Inc. ^{1,2,3}	7,158,990	69,800
	MKS Instruments, Inc.	546,356	65,142
	GitLab, Inc., Class A ¹	1,074,258	50,920
	HubSpot, Inc. ¹	81,417	40,633
	Stripe, Inc., Class B ^{1,4,5}	1,153,942	31,74!
	Nutanix, Inc., Class A ¹	456,200	28,82
	Seagate Technology Holdings PLC	251,452	25,032
	SK hynix, Inc.	91,219	11,934
			73,352,033
Consumer	Amazon.com, Inc. ¹	57,452,037	10,255,189
discretionary	Tesla, Inc. ¹	23,417,317	5,013,882
14.66%	Royal Caribbean Cruises, Ltd. ^{1,3}	23,595,011	3,884,21
	Chipotle Mexican Grill, Inc. ¹	33,175,634	1,860,490
	DoorDash, Inc., Class A ¹	13,291,986	1,710,812
	Flutter Entertainment PLC ¹	7,821,780	1,661,42
	D.R. Horton, Inc.	7,735,589	1,460,170
	Airbnb, Inc., Class A ¹	10,407,630	1,220,919
	MercadoLibre, Inc. ¹	518,191	1,068,334

	ks (continued)	Shares	(000
Consumer	NVR, Inc. ¹	94,545	\$ 867,210
discretionary	Home Depot, Inc.	2,334,955	860,431
(continued)	LVMH Moët Hennessy-Louis Vuitton SE	1,139,466	854,736
	Hermès International	279,536	670,608
	Tractor Supply Co.	2,451,742	655,964
	Las Vegas Sands Corp.	16,429,110	640,571
	Hilton Worldwide Holdings, Inc.	2,837,955	623,328
	General Motors Co.	11,154,593	555,276
	Burlington Stores, Inc. ¹	1,900,277	509,730
	Floor & Decor Holdings, Inc., Class A ¹	4,270,796	480,208
	Coupang, Inc., Class A ¹	21,473,603	475,640
	Caesars Entertainment, Inc. ^{1,3}	12,359,626	465,216
	Evolution AB	4,065,181	423,141
	Starbucks Corp.	4,166,667	394,042
	Lennar Corp., Class A	2,152,408	391,867
	Mattel, Inc. ^{1,3}	17,223,802	326,908
	Wayfair, Inc., Class A ¹	7,666,564	326,212
	Polaris, Inc. ³	3,844,398	325,428
	NIKE, Inc., Class B	3,580,491	298,327
	MGM Resorts International	6,455,000	242,643
	lululemon athletica, Inc. ¹	919,764	238,651
	Aptiv PLC ¹	2,825,072	202,077
	Toll Brothers, Inc.	1,299,194	187,175
	Amadeus IT Group SA, Class A, non-registered shares	2,608,871	176,029
	TopBuild Corp. ¹	441,459	173,502
	adidas AG	674,261	172,475
	Norwegian Cruise Line Holdings, Ltd. ¹	9,579,858	171,384
	DraftKings, Inc., Class A ¹	4,435,959	153,041
	Ferrari NV (EUR denominated)	297,675	147,946
	Service Corp. International	1,624,261	127,131
	Aramark	3,362,081	123,153
	YUM! Brands, Inc.	670,147	90,416
	YETI Holdings, Inc. ¹	1,717,972	69,269
	Marriott International, Inc., Class A	215,582	50,595
	Darden Restaurants, Inc.	313,036	49,507
	Churchill Downs, Inc.	336,203	46,722
			41,741,935
Health care	Eli Lilly and Co.	7,515,535	7,215,064
44 5 / 0/			7,210,00
14.56%	UnitedHealth Group, Inc.	9,529,722	5,624,442
14.56%	UnitedHealth Group, Inc. Vertex Pharmaceuticals, Inc. ¹	9,529,722 8,128,326	
14.56%			5,624,442
14.50%	Vertex Pharmaceuticals, Inc. ¹	8,128,326	5,624,442 4,030,756
14.50%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹	8,128,326 3,135,480	5,624,442 4,030,756 3,714,572
14.50%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹ Alnylam Pharmaceuticals, Inc. ^{1,3}	8,128,326 3,135,480 10,609,427	5,624,442 4,030,756 3,714,572 2,786,990
14.50%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹ Alnylam Pharmaceuticals, Inc. ^{1,3} Thermo Fisher Scientific, Inc.	8,128,326 3,135,480 10,609,427 3,627,613	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236
14.50%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹ Alnylam Pharmaceuticals, Inc. ^{1,3} Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc. ¹	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882
14.50%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹ Alnylam Pharmaceuticals, Inc. ^{1,3} Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc. ¹ Novo Nordisk AS, Class B	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922
14.50%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹ Alnylam Pharmaceuticals, Inc. ^{1,3} Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc. ¹ Novo Nordisk AS, Class B Boston Scientific Corp. ¹	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632
14.50%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹ Alnylam Pharmaceuticals, Inc. ^{1,3} Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc. ¹ Novo Nordisk AS, Class B Boston Scientific Corp. ¹ GE HealthCare Technologies, Inc.	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684
14.50%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹ Alnylam Pharmaceuticals, Inc. ^{1,3} Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc. ¹ Novo Nordisk AS, Class B Boston Scientific Corp. ¹ GE HealthCare Technologies, Inc. Danaher Corp.	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092
14.50%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹ Alnylam Pharmaceuticals, Inc. ^{1,3} Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc. ¹ Novo Nordisk AS, Class B Boston Scientific Corp. ¹ GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc.	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152
14.50%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹ Alnylam Pharmaceuticals, Inc. ^{1,3} Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc. ¹ Novo Nordisk AS, Class B Boston Scientific Corp. ¹ GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp.	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884
14.50%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹ Alnylam Pharmaceuticals, Inc. ^{1,3} Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc. ¹ Novo Nordisk AS, Class B Boston Scientific Corp. ¹ GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp. Abbott Laboratories	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848 6,699,456	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884 758,847
14.50%	Vertex Pharmaceuticals, Inc. 1 Regeneron Pharmaceuticals, Inc. 1 Alnylam Pharmaceuticals, Inc. 1,3 Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc. 1 Novo Nordisk AS, Class B Boston Scientific Corp. 1 GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp. Abbott Laboratories Exact Sciences Corp. 1	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848 6,699,456 8,496,745	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884
14.50%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹ Alnylam Pharmaceuticals, Inc. ^{1,3} Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc. ¹ Novo Nordisk AS, Class B Boston Scientific Corp. ¹ GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp. Abbott Laboratories Exact Sciences Corp. ¹ Mettler-Toledo International, Inc. ¹	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848 6,699,456 8,496,745 321,380	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884 758,847 524,164
14.50%	Vertex Pharmaceuticals, Inc. 1 Regeneron Pharmaceuticals, Inc. 1 Alnylam Pharmaceuticals, Inc. 1,3 Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc. 1 Novo Nordisk AS, Class B Boston Scientific Corp. 1 GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp. Abbott Laboratories Exact Sciences Corp. 1 Mettler-Toledo International, Inc. 1 BioMarin Pharmaceutical, Inc. 1	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848 6,699,456 8,496,745 321,380 4,971,836	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884 758,847 524,164 462,492 453,481
14.50%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹ Alnylam Pharmaceuticals, Inc. ^{1,3} Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc. ¹ Novo Nordisk AS, Class B Boston Scientific Corp. ¹ GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp. Abbott Laboratories Exact Sciences Corp. ¹ Mettler-Toledo International, Inc. ¹ BioMarin Pharmaceutical, Inc. ¹ Molina Healthcare, Inc. ¹	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848 6,699,456 8,496,745 321,380 4,971,836 1,294,307	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884 758,847 524,164 462,492 453,481
14.30%	Vertex Pharmaceuticals, Inc. ¹ Regeneron Pharmaceuticals, Inc. ¹ Alnylam Pharmaceuticals, Inc. ^{1,3} Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc. ¹ Novo Nordisk AS, Class B Boston Scientific Corp. ¹ GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp. Abbott Laboratories Exact Sciences Corp. ¹ Mettler-Toledo International, Inc. ¹ BioMarin Pharmaceutical, Inc. ¹ DexCom, Inc. ¹	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848 6,699,456 8,496,745 321,380 4,971,836 1,294,307 6,356,543	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884 758,847 524,164 462,492 453,481 452,736
14.50%	Vertex Pharmaceuticals, Inc.¹ Regeneron Pharmaceuticals, Inc.¹ Alnylam Pharmaceuticals, Inc.¹,3 Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc.¹ Novo Nordisk AS, Class B Boston Scientific Corp.¹ GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp. Abbott Laboratories Exact Sciences Corp.¹ Mettler-Toledo International, Inc.¹ BioMarin Pharmaceutical, Inc.¹ DexCom, Inc.¹ Humana, Inc.¹	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848 6,699,456 8,496,745 321,380 4,971,836 1,294,307 6,356,543 1,134,986 1,094,267	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884 758,847 524,164 462,492 453,481 452,736 440,763
14.50%	Vertex Pharmaceuticals, Inc.¹ Regeneron Pharmaceuticals, Inc.¹ Alnylam Pharmaceuticals, Inc.¹,³ Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc.¹ Novo Nordisk AS, Class B Boston Scientific Corp.¹ GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp. Abbott Laboratories Exact Sciences Corp.¹ Mettler-Toledo International, Inc.¹ BioMarin Pharmaceutical, Inc.¹ Molina Healthcare, Inc.¹ DexCom, Inc.¹ Humana, Inc. Amgen, Inc. Centene Corp.¹	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848 6,699,456 8,496,745 321,380 4,971,836 1,294,307 6,356,543 1,134,986 1,094,267 4,327,633	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884 758,847 524,164 462,492 453,481 452,736 440,763 402,318 365,299 341,147
14.30%	Vertex Pharmaceuticals, Inc.¹ Regeneron Pharmaceuticals, Inc.¹ Alnylam Pharmaceuticals, Inc.¹,3 Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc.¹ Novo Nordisk AS, Class B Boston Scientific Corp.¹ GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp. Abbott Laboratories Exact Sciences Corp.¹ Mettler-Toledo International, Inc.¹ BioMarin Pharmaceutical, Inc.¹ DexCom, Inc.¹ Humana, Inc. Amgen, Inc.	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848 6,699,456 8,496,745 321,380 4,971,836 1,294,307 6,356,543 1,134,986 1,094,267 4,327,633 1,404,830	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884 758,847 524,164 462,492 453,481 452,736 440,763 402,318 365,299 341,147 284,857
14.50%	Vertex Pharmaceuticals, Inc.¹ Regeneron Pharmaceuticals, Inc.¹ Alnylam Pharmaceuticals, Inc.¹,3 Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc.¹ Novo Nordisk AS, Class B Boston Scientific Corp.¹ GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp. Abbott Laboratories Exact Sciences Corp.¹ Mettler-Toledo International, Inc.¹ BioMarin Pharmaceutical, Inc.¹ Molina Healthcare, Inc.¹ DexCom, Inc.¹ Humana, Inc. Amgen, Inc. Centene Corp.¹ Insulet Corp.¹	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848 6,699,456 8,496,745 321,380 4,971,836 1,294,307 6,356,543 1,134,986 1,094,267 4,327,633 1,404,830 1,400,368	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884 758,847 524,164 462,492 453,481 452,736 440,763 402,318 365,299 341,147 284,857 274,906
14.50%	Vertex Pharmaceuticals, Inc.¹ Regeneron Pharmaceuticals, Inc.¹ Alnylam Pharmaceuticals, Inc.¹,3 Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc.¹ Novo Nordisk AS, Class B Boston Scientific Corp.¹ GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp. Abbott Laboratories Exact Sciences Corp.¹ Mettler-Toledo International, Inc.¹ BioMarin Pharmaceutical, Inc.¹ Molina Healthcare, Inc.¹ DexCom, Inc.¹ Humana, Inc. Amgen, Inc. Centene Corp.¹ Insulet Corp.¹ AbbVie, Inc. Insmed, Inc.¹	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848 6,699,456 8,496,745 321,380 4,971,836 1,294,307 6,356,543 1,134,986 1,094,267 4,327,633 1,404,830 1,400,368 3,591,586	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884 758,847 524,164 462,492 453,483 440,763 440,763 440,763 440,763 421,147 284,857 274,906 274,649
14.50%	Vertex Pharmaceuticals, Inc.¹ Regeneron Pharmaceuticals, Inc.¹ Alnylam Pharmaceuticals, Inc.¹,3 Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc.¹ Novo Nordisk AS, Class B Boston Scientific Corp.¹ GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp. Abbott Laboratories Exact Sciences Corp.¹ Mettler-Toledo International, Inc.¹ BioMarin Pharmaceutical, Inc.¹ Molina Healthcare, Inc.¹ DexCom, Inc.¹ Humana, Inc. Amgen, Inc. Centene Corp.¹ Insulet Corp.¹ AbbVie, Inc. Insmed, Inc.¹ Veeva Systems, Inc., Class A¹	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848 6,699,456 8,496,745 321,380 4,971,836 1,294,307 6,356,543 1,134,986 1,094,267 4,327,633 1,404,830 1,400,368 3,591,586 1,203,499	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884 758,847 524,164 462,492 453,481 452,736 440,763 440,763 440,763 42,318 365,299 341,147 284,857 274,906 274,649 260,485
14.50%	Vertex Pharmaceuticals, Inc.¹ Regeneron Pharmaceuticals, Inc.¹ Alnylam Pharmaceuticals, Inc.¹,3 Thermo Fisher Scientific, Inc. Intuitive Surgical, Inc.¹ Novo Nordisk AS, Class B Boston Scientific Corp.¹ GE HealthCare Technologies, Inc. Danaher Corp. HCA Healthcare, Inc. Stryker Corp. Abbott Laboratories Exact Sciences Corp.¹ Mettler-Toledo International, Inc.¹ BioMarin Pharmaceutical, Inc.¹ Molina Healthcare, Inc.¹ DexCom, Inc.¹ Humana, Inc. Amgen, Inc. Centene Corp.¹ Insulet Corp.¹ AbbVie, Inc. Insmed, Inc.¹	8,128,326 3,135,480 10,609,427 3,627,613 3,935,777 10,176,286 16,990,239 13,613,351 3,624,419 2,222,381 2,138,848 6,699,456 8,496,745 321,380 4,971,836 1,294,307 6,356,543 1,134,986 1,094,267 4,327,633 1,404,830 1,400,368 3,591,586	5,624,442 4,030,756 3,714,572 2,786,990 2,231,236 1,938,882 1,416,922 1,389,632 1,154,684 976,092 879,152 770,884 758,847 524,164 462,492 453,483 440,763 440,763 440,763 440,763 421,147 284,857 274,906 274,649

Common stock	(S (continued)	Shares	Value (000)
Health care	Align Technology, Inc. ¹	739,549	\$ 175,436
(continued)	Ascendis Pharma AS (ADR) ¹	1,063,909	147,298
	IQVIA Holdings, Inc. ¹	552,000	138,856
	QIAGEN NV ¹ AstraZeneca PLC	2,816,196 631,582	128,728 110,362
	Vaxcyte, Inc. ¹	1,213,806	98,027
	CVS Health Corp.	1,669,728	95,575
	Daiichi Sankyo Co., Ltd.	1,823,000	76,672
	Elevance Health, Inc.	126,879	70,658
	Verily Life Sciences, LLC ^{1,4,5}	673,374	70,327
	NovoCure, Ltd. ¹ BeiGene, Ltd. (ADR) ¹	3,302,638 304,995	64,203 58,492
	CRISPR Therapeutics AG ^{1,2}	870,389	41,535
	Guardant Health, Inc. ¹	1,559,981	39,904
	Ionis Pharmaceuticals, Inc. ¹	825,527	39,361
	Biohaven, Ltd. ¹	271,571	10,700
	agilon health, Inc. ¹	1,639,529	6,689
			41,480,203
Communication	Meta Platforms, Inc., Class A	30,370,029	15,832,200
services	Alphabet, Inc., Class A	34,732,142	5,674,538
12.84%	Alphabet, Inc., Class C	32,717,439	5,401,976
	Netflix, Inc. ¹	8,273,855	5,802,868
	Charter Communications, Inc., Class A ¹	3,368,573	1,170,714
	Tencent Holdings, Ltd. Take-Two Interactive Software, Inc. ¹	17,665,100 3,089,569	853,790 499,614
	T-Mobile US, Inc.	1,823,710	362,408
	Snap, Inc., Class A, nonvoting shares ¹	29,899,824	279,264
	Frontier Communications Parent, Inc. ¹	7,968,994	229,507
	Verizon Communications, Inc.	5,254,396	219,529
	Comcast Corp., Class A	3,408,612	134,879
	Pinterest, Inc., Class A ¹ Epic Games, Inc. ^{1,4,5}	1,897,900 84,249	60,809 50,549
	1	. ,	36,572,645
		04 / 40 500	4 202 000
Industrials 11.98%	General Electric Co. TransDigm Group, Inc.	24,642,582 2,711,650	4,303,088 3,723,665
1117070	Uber Technologies, Inc. ¹	46,695,206	3,414,820
	Carrier Global Corp.	41,645,582	3,030,965
	Boeing Co. ¹	16,540,347	2,873,720
	United Rentals, Inc.	2,748,823	2,037,592
	Caterpillar, Inc.	4,609,284	1,641,366
	Ingersoll-Rand, Inc. Republic Services, Inc.	15,341,101 3,970,237	1,402,944 826,643
	Airbus SE, non-registered shares	5,100,993	786,219
	Safran SA	3,329,717	729,034
	Delta Air Lines, Inc.	15,674,419	666,006
	XPO, Inc. ¹	5,565,930	637,967
	Axon Enterprise, Inc. ¹	1,736,411	633,738
	Eaton Corp. PLC Recruit Holdings Co., Ltd.	1,956,317 9,427,700	600,452 588,744
	United Airlines Holdings, Inc. ¹	12,788,697	563,214
	HEICO Corp.	1,887,899	484,360
	HEICO Corp., Class A	303,660	60,759
			4/4007
	GE Vernova, Inc. ¹	2,308,642	464,037
	GE Vernova, Inc. ¹ Ryanair Holdings PLC (ADR)	3,983,891	444,045
	GE Vernova, Inc. ¹ Ryanair Holdings PLC (ADR) Ryanair Holdings PLC	3,983,891 315,525	444,045 5,579
	GE Vernova, Inc. ¹ Ryanair Holdings PLC (ADR) Ryanair Holdings PLC Equifax, Inc.	3,983,891 315,525 1,345,248	444,045 5,579 413,166
	GE Vernova, Inc. ¹ Ryanair Holdings PLC (ADR) Ryanair Holdings PLC	3,983,891 315,525	444,045 5,579 413,166 392,479
	GE Vernova, Inc. ¹ Ryanair Holdings PLC (ADR) Ryanair Holdings PLC Equifax, Inc. Union Pacific Corp.	3,983,891 315,525 1,345,248 1,532,584	444,045 5,579 413,166 392,479 363,840
	GE Vernova, Inc. ¹ Ryanair Holdings PLC (ADR) Ryanair Holdings PLC Equifax, Inc. Union Pacific Corp. Dayforce, Inc. ¹ Southwest Airlines Co. Old Dominion Freight Line, Inc.	3,983,891 315,525 1,345,248 1,532,584 6,364,176 12,468,249 1,833,856	444,045 5,579 413,166 392,479 363,840 360,582 353,567
	GE Vernova, Inc. ¹ Ryanair Holdings PLC (ADR) Ryanair Holdings PLC Equifax, Inc. Union Pacific Corp. Dayforce, Inc. ¹ Southwest Airlines Co. Old Dominion Freight Line, Inc. Saia, Inc. ¹	3,983,891 315,525 1,345,248 1,532,584 6,364,176 12,468,249 1,833,856 874,192	444,045 5,579 413,166 392,479 363,840 360,582 353,567 328,548
	GE Vernova, Inc. ¹ Ryanair Holdings PLC (ADR) Ryanair Holdings PLC Equifax, Inc. Union Pacific Corp. Dayforce, Inc. ¹ Southwest Airlines Co. Old Dominion Freight Line, Inc.	3,983,891 315,525 1,345,248 1,532,584 6,364,176 12,468,249 1,833,856	444,045 5,579 413,166 392,479 363,840 360,582 353,567

Common stocks (continued)		Shares	Value (000)
Industrials (continued)	Core & Main, Inc., Class A ¹ Generac Holdings, Inc. ¹ Paylocity Holding Corp. ¹ Canadian Pacific Kansas City, Ltd. FedEx Corp. RTX Corp. APi Group Corp. ¹ WillScot Holdings Corp., Class A ¹ Daikin Industries, Ltd. Simpson Manufacturing Co., Inc. Bombardier, Inc., Class B ¹ GFL Environmental, Inc., subordinate voting shares Einride AB ^{1,4,5}	3,986,477 942,790 899,483 1,728,944 470,123 1,046,024 2,878,565 1,961,020 560,000 342,274 541,102 437,700 267,404	\$ 191,470 147,575 145,177 143,399 140,459 129,017 102,333 75,578 71,263 62,657 37,164 18,957 7,728
Financials 8.72%	Mastercard, Inc., Class A KKR & Co., Inc. Visa, Inc., Class A Progressive Corp. BlackRock, Inc. Affirm Holdings, Inc., Class A¹ Blackstone, Inc. Apollo Asset Management, Inc. Goldman Sachs Group, Inc. Wells Fargo & Co. Discover Financial Services Marsh & McLennan Companies, Inc. Berkshire Hathaway, Inc., Class B¹ Toast, Inc., Class A¹ Brookfield Corp., Class A Bank of America Corp. Blue Owl Capital, Inc., Class A MSCI, Inc. Nu Holdings, Ltd., Class A¹ Morgan Stanley UBS Group AG Ryan Specialty Holdings, Inc., Class A East West Bancorp, Inc. Essent Group, Ltd.³ PNC Financial Services Group, Inc. PayPal Holdings, Inc.¹ JPMorgan Chase & Co. Chubb, Ltd. Ares Management Corp., Class A Fisery, Inc.¹ Block, Inc., Class A¹ Capital One Financial Corp. Intercontinental Exchange, Inc. AIA Group, Ltd.¹ American International Group, Inc. Arch Capital Group, Ltd.¹ Tradeweb Markets, Inc., Class A First Citizens BancShares, Inc., Class A T. Rowe Price Group, Inc. Trupanion, Inc.¹ Citigroup, Inc. S&P Global, Inc. Fannie Mae¹.²	9,023,379 19,121,536 7,286,397 6,207,692 1,150,538 21,107,015 5,853,658 7,140,192 1,474,070 11,065,023 4,623,650 2,670,324 1,215,489 22,903,250 10,688,135 13,171,079 25,100,233 727,384 27,895,166 3,697,932 12,079,690 5,627,421 4,208,670 5,446,751 1,750,826 3,464,484 1,080,876 1,146,877 2,679,961 1,075,254 971,217 19,275,888 1,710,446 1,086,485 1,025,594 52,951 908,955 1,979,054 1,327,988 87,615 3,620,466	4,361,360 2,366,672 2,013,742 1,565,580 1,037,567 928,920 833,327 826,334 752,144 646,972 641,346 607,525 578,475 569,375 537,399 536,721 442,768 422,312 417,591 383,143 369,939 363,700 353,823 350,172 324,060 250,933 242,976 239,962 234,958 200,245 177,092 157,987 156,900 137,493 131,790 122,871 121,266 107,528 96,386 90,502 83,185 44,967 4,345
Energy 2.68%	EOG Resources, Inc. Cenovus Energy, Inc. (CAD denominated) Cenovus Energy, Inc. Canadian Natural Resources, Ltd. (CAD denominated) Halliburton Co. Schlumberger NV	13,024,105 47,784,438 18,837,206 24,985,107 25,631,299 17,751,652	24,832,353 1,677,765 886,085 349,242 904,370 796,877 780,895

Common stocks	(continued)	Shares	Value (000)
Energy (continued)	ConocoPhillips Exxon Mobil Corp.	5,668,604 5,101,270	\$ 645,030 601,644
	Chevron Corp.	2,559,602	378,693
	Cheniere Energy, Inc.	1,800,966	333,647
	Tourmaline Oil Corp. ² Weatherford International	3,262,639	148,697
	vveatherrord international	1,241,240	7,633,201
Materials 2.14%	Linde PLC Freeport-McMoRan, Inc.	2,884,066 20,473,935	1,379,304 906,586
2.1.170	Celanese Corp. ³	6,897,250	900,781
	Sherwin-Williams Co.	1,923,459	710,468
	Sika AG	1,356,820	434,901
	ATI, Inc. ¹	5,994,109	382,904
	Steel Dynamics, Inc.	2,733,506	326,681
	Glencore PLC	38,011,292	201,437
	Air Products and Chemicals, Inc.	700,000 2,000,000	195,195
	Albemarle Corp. Vulcan Materials Co.	2,000,000 672,949	180,500 165,014
	Lundin Mining Corp.	14,110,481	146,377
	Barrick Gold Corp.	7,077,141	142,887
	Shin-Etsu Chemical Co., Ltd.	655,000	29,035
			6,102,070
Consumer staples	Philip Morris International, Inc.	13,374,284	1,648,915
1.93%	Costco Wholesale Corp.	1,172,858	1,046,635
	Target Corp.	2,576,368	395,782
	British American Tobacco PLC	9,819,777	367,055
	Keurig Dr Pepper, Inc.	8,768,906	321,030
	Performance Food Group Co. ¹	3,843,642	286,889
	Monster Beverage Corp. ¹ L'Oréal SA, non-registered shares	5,250,669 322,893	247,464 141,630
	L'Oréal SA, hon-registered shares L'Oréal SA, bonus shares	230,933	101,294
	Celsius Holdings, Inc. ¹	6,074,755	231,023
	Dollar General Corp.	2,332,059	193,491
	Dollar Tree Stores, İnc. ¹	1,816,396	153,467
	Constellation Brands, Inc., Class A	585,680	140,979
	Avenue Supermarts, Ltd. ¹	2,130,914	125,520
	Fever-Tree Drinks PLC ³	7,030,723	5,483,694
Utilities	Constellation Energy Corp.	5,156,994	1,014,381
0.75%	PG&E Corp. AES Corp.	39,718,989 10,590,104	782,464 181,408
	NextEra Energy, Inc.	2,031,485	163,555
	Notice Energy, inc.	2,001,100	2,141,808
Real estate	Zillow Group, Inc., Class C, nonvoting shares ¹	5,369,388	296,927
0.20%	CoStar Group, Inc. ¹ Crown Castle, Inc. REIT	2,850,314 379,728	220,329
	American Tower Corp. REIT	99,900	42,537 22,384
	American tower corp. NET	77,700	
	Total common stocks (cost: \$118,863,817,000)		582,177 274,043,945
Preferred securi	ties 0.33%		
Financials	Fannie Mae, Series S, 8.25% noncumulative preferred shares ¹	49,820,138	212,234
0.16%	Fannie Mae, Series T, 8.25% noncumulative preferred shares ¹	6,954,484 1,739,366	26,358 11 210
	Fannie Mae, Series O, 7.00% noncumulative preferred shares ¹ Fannie Mae, Series R, 7.625% noncumulative preferred shares ¹	1,739,366 837,675	11,219 2,699
	Fannie Mae, Series N, 7.023 % Honcumulative preferred shares Fannie Mae, Series P, (3-month USD-LIBOR + 0.75%)	007,073	2,077
	6.288% noncumulative preferred shares ^{1,6,7}	190,000	564
	5.25070 No. 100 No. 100 Protection of the total	170,000	304

Preferred secu	urities (continued)	Shares	Value (000)
Financials (continued)	Federal Home Loan Mortgage Corp., Series Z, 8.375% noncumulative preferred shares ^{1,2} Federal Home Loan Mortgage Corp., Series X, 6.02% noncumulative preferred shares ¹ Federal Home Loan Mortgage Corp., Series V, 5.57% noncumulative preferred shares ¹	53,399,510 239,000 212,500	\$ 210,928 741 646 465,389
Information	Stripe, Inc., Series I, 6.00% noncumulative preferred shares ^{1,4,5} Stripe, Inc., Series BB-1, 6.00% noncumulative preferred shares ^{1,4,5}	7,098,300	195,274
technology 0.11%	Stripe, Inc., Series Bb-1, 6.00% noncumulative preferred shares ^{1,4,5}	604,130 396,250	16,620 10,901
0,0	Stripe, Inc., Series H, 6.00% noncumulative preferred shares ^{1,4,5}	376,444	10,356
	Stripe, Inc., Series BB, 6.00% noncumulative preferred shares 1,4,5	214,287	5,895
	Chime Financial, Inc., Series G, preferred shares 1,4,5	1,433,730	37,965
	PsiQuantum Corp., Series D, preferred shares ^{1,4,5} Tipalti Solutions, Ltd., Series F, preferred shares ^{1,4,5}	613,889 3,800,381	24,408 20,104
	ripaiti Solutions, Ltd., Series I., preferred shares	3,000,301	321,523
Consumer	Waymo, LLC, Series A-2, 8.00% noncumulative preferred shares 1,4,5	1,164,589	91,072
discretionary	Waymo, LLC, Series B-2, noncumulative preferred shares 1,4,5	163,537	12,789
0.05%	GM Cruise Holdings, LLC, Series F, preferred shares ^{1,4,5}	5,205,500	20,510
			124,371
 Industrials	ABL Space Systems Co., Series B2, 5.00% PIK cumulative preferred shares 1,4,5,8	576,000	18,836
0.01%	ABL Space Systems Co., Series C1, 5.00% cumulative preferred shares 1,4,5	188,983	6,180
	Einride AB, Series C, preferred shares ^{1,4,5}	375,684	10,857
			35,873
	Total preferred securities (cost: \$1,154,981,000)		947,156
Rights & warra	ants 0.00%		
Information	Constellation Software, Inc., warrants, expire 3/31/2040 ^{1,4}	180,549	_
technology 0.00%			
Industrials	ABL Space Systems Co., Series C-1, warrants, expire 12/13/2030 ^{1,4,5}	141,737	_
0.00%	Total rights & warrants (cost: \$0)		
Short-term sec	curities 3.54%		
	vestments 3.46%		
	Capital Group Central Cash Fund 5.30% ^{3,10}	98,343,177	9,837,268
Money market in	vestments purchased with collateral from securities on loan 0.08%		
	Capital Group Central Cash Fund 5.30% ^{3,10,11} State Street Institutional U.S. Government Money Market Fund,	1,799,872	180,041
	Institutional Class 5.21% ^{10,11}	50,289,053	50,289
	Invesco Short-Term Investments Trust - Government & Agency Portfolio,	00 502	00
	Institutional Class 5.18% ^{10,11}	82,593	83
			230,413
	Total short-term securities (cost: \$10,064,302,000)		10,067,681
	Total investment securities 100.08% (cost: \$130,083,100,000)		285,058,782
	Other assets less liabilities (0.08)%		(224,014
	Net assets 100.00%		\$284,834,768

	Value at 9/1/2023 (000)	Additions (000)	Reductions (000)	Net realized gain (loss) (000)	unrealized appreciation (depreciation) (000)	Value at 8/31/2024 (000)	Dividend or interest income (000)
Common stocks 3.23%							
Information technology 0.02%							
Wolfspeed, Inc. ^{1,2}	\$ 422,651	\$ -	\$ 21,368	\$(147,559)	\$ (183,924)	\$ 69,800	\$ -
Consumer discretionary 1.76%							
Royal Caribbean Cruises, Ltd. ¹	2,024,207	466,752	6,233	4,772	1,394,713	3,884,211	_
Caesars Entertainment, Inc. ¹	1,099,391	115,086	453,655	(237,414)	(58,192)	465,216	-
Mattel, Inc. ¹	360,907	23,353	5,395	(138)	(51,819)	326,908	_
Polaris, Inc.	432,362	_	1,344	89	(105,679)	325,428	7,573
Floor & Decor Holdings, Inc., Class A ^{1,12}	532,171	89,533	176,361	1,030	33,835	-	-
Norwegian Cruise Line Holdings, Ltd. 1,12	295,756	270,313	376,584	(50,700)	32,599		-
Health care 0.98%							
Alnylam Pharmaceuticals, Inc. ¹	1,560,126	773,105	70,869	(35,823)	560,451	2,786,990	
Karuna Therapeutics, Inc. 13	456,981	3,866	70,869	355,422	(37,023)	2,100,770	_
NovoCure, Ltd. ^{1,12}	160,270	5,000	54,945	(220,876)	179,754	_	
Novocure, Eta.	100,270	_	34,743	(220,070)	177,734	2,786,990	_
Industrials 0.00%							
Carrier Global Corp. 12	2,909,404	39,149	491,982	128,741	445,653	_	33,228
Chart Industries, Inc. 13	477,436	_	391,024	(33,012)	(53,400)	-	_
Robert Half, Inc. ¹³	337,490	56,396	403,595	(129,717)	139,426	-	4,530
TransDigm Group, Inc. 12	2,539,884	20,053	152,321	58,560	1,257,489		98,702
Financials 0.12%							
Essent Group, Ltd.	274,452	_	883	142	76,461	350,172	5,937
Energy 0.00%	27.1,102		000		, 0, .0 .	000,.,2	0,707
Weatherford International ¹²	403,051		357,057	268,481	(184,219)		310
	403,031		337,037	200,401	(104,217)		310
Materials 0.32%	0// 172	7 002	2.027	F20	20.022	000 701	10 212
Celanese Corp.	866,173	7,882	2,836	529	29,033	900,781	19,312
Consumer staples 0.03%							
Fever-Tree Drinks PLC	123,685	_	4,860	(9,185)	(27,120)	82,520	1,541
Total common stocks						9,192,026	
Short-term securities 3.53%							
Money market investments 3.46%							
Capital Group Central Cash Fund 5.30% ¹⁰ Money market investments purchased with collateral	12,077,710	23,045,189	25,288,211	1,135	1,445	9,837,268	584,676
from securities on loan 0.07%							
Capital Group Central Cash Fund 5.30% ^{10,11}	61,987	118,054 ¹⁴				180,041	_1
Total short-term securities						10,017,309	
Total 6.76%				\$ (45,523) ======	\$3,449,483	\$19,209,335 	\$755,809 ======
Restricted securities ⁵							
		Δ		6 .	V. I		Percent
		Acquisition date(s		Cost (000)	Val (00		of net assets
Stripe, Inc., Series I, 6.00% noncumulative preferred shar	es ^{1,4}	3/15/2023	}	5142,918	\$195,2	74	.07%
Stripe, Inc., Class B ^{1,4}		2021-8/24/2023		45,738	31,7		.01
Stripe, Inc., Series BB-1, 6.00% noncumulative preferred		8/24/2023		13,012	16,6		.01
Stripe, Inc., Series G, 6.00% noncumulative preferred sha		9/29/2023		8,909	10,9		.0016

Restricted securities⁵ (continued)

	Acquisition date(s)	Cost (000)	Value (000)	Percent of net assets
Stripe, Inc., Series H, 6.00% noncumulative preferred shares ^{1,4}	3/15/2021	\$ 15,105	\$ 10,356	.00% ¹⁶
Stripe, Inc., Series BB, 6.00% noncumulative preferred shares ^{1,4}	8/24/2023	4,615	5,895	.0016
Waymo, LLC, Series A-2, 8.00% noncumulative preferred shares 1,4	5/1/2020	100,000	91,072	.03
Waymo, LLC, Series B-2, noncumulative preferred shares ^{1,4}	6/11/2021	15,000	12,789	.01
Verily Life Sciences, LLC ^{1,4}	12/21/2018	83,000	70,327	.02
Epic Games, Inc. ^{1,4}	3/29/2021	74,560	50,549	.02
Chime Financial, Inc., Series G, preferred shares ^{1,4}	8/24/2021	99,027	37,965	.01
ABL Space Systems Co., Series B2, 5.00% PIK cumulative preferred				
shares ^{1,4,8}	10/22/2021	39,166	18,836	.01
ABL Space Systems Co., Series C1, 5.00% cumulative preferred				
shares ^{1,4}	12/14/2023	6,180	6,180	.0016
ABL Space Systems Co., Series C-1, warrants, expire 12/13/2030 ^{1,4}	12/14/2023	_9	_9	.0016
PsiQuantum Corp., Series D, preferred shares ^{1,4}	5/28/2021	16,100	24,408	.01
GM Cruise Holdings, LLC, Series F, preferred shares ^{1,4}	5/7/2020	95,000	20,510	.01
Tipalti Solutions, Ltd., Series F, preferred shares ^{1,4}	12/1/2021	65,064	20,104	.01
Einride AB, Series C, preferred shares ^{1,4}	11/23/2022-5/3/2024	12,773	10,857	.01
Einride AB ^{1,4}	2/1/2023	9,092	7,728	.0016
Total		\$845,259	\$642,116	.23%

¹Security did not produce income during the last 12 months.

Key to abbreviation(s)

ADR = American Depositary Receipts

CAD = Canadian dollars

EUR = Euros

LIBOR = London Interbank Offered Rate

PIK = Payment In Kind

REIT = Real Estate Investment Trust

²All or a portion of this security was on loan. The total value of all such securities was \$242,201,000, which represented .09% of the net assets of the fund. Refer to Note 5 for more information on securities lending.

³Affiliate of the fund or part of the same "group of investment companies" as the fund, as defined under the Investment Company Act of 1940, as amended.

⁴Value determined using significant unobservable inputs.

⁵Restricted security, other than Rule 144A securities or commercial paper issued pursuant to Section 4(a)(2) of the Securities Act of 1933. The total value of all such restricted securities was \$642,116,000, which represented .23% of the net assets of the fund.

⁶Securities referencing LIBOR are expected to transition to an alternative reference rate by the security's next scheduled coupon reset date.

⁷Coupon rate may change periodically. Reference rate and spread are as of the most recent information available. Some coupon rates are determined by the issuer or agent based on current market conditions; therefore, the reference rate and spread are not available.

⁸Payment in kind; the issuer has the option of paying additional securities in lieu of cash. Payment methods and rates are as of the most recent payment when available.

⁹Amount less than one thousand.

¹⁰Rate represents the seven-day yield at 8/31/2024.

¹¹Security purchased with cash collateral from securities on loan. Refer to Note 5 for more information on securities lending.

¹² Affiliated issuer during the reporting period but no longer an affiliate at 8/31/2024. Refer to the investment portfolio for the security value at 8/31/2024.

¹³Affiliated issuer during the reporting period but no longer held at 8/31/2024.

¹⁴Represents net activity. Refer to Note 5 for more information on securities lending.

¹⁵ Dividend income is included with securities lending income in the fund's statement of operations and is not shown in this table.

¹⁶Amount less than .01%.

Financial statements

Statement of assets and liabilities at August 31, 2024

		(dollars in thousands)
Assets:		
Investment securities, at value (includes \$242,201 of		
investment securities on loan):		
Unaffiliated issuers (cost: \$113,846,183)	\$265,849,447	
Affiliated issuers (cost: \$16,236,917)	19,209,335	\$285,058,782
Cash		6,554
Cash denominated in currencies other than U.S. dollars (cost: \$3)		3
Cash collateral received for securities on loan		25,601
Receivables for:		
Sales of investments	182,364	
Sales of fund's shares	122,109	
Dividends and interest	153,353	
Securities lending income	143	
Other	303	458,272
		285,549,212
Liabilities:		
Collateral for securities on loan		256,014
Payables for:		
Purchases of investments	179,661	
Repurchases of fund's shares	152,116	
Investment advisory services	59,899	
Services provided by related parties	53,253	
Trustees' deferred compensation	7,791	
Other	5,710	458,430
Net assets at August 31, 2024		\$284,834,768
Net assets consist of:		
Capital paid in on shares of beneficial interest		\$111,680,964
Total distributable earnings (accumulated loss)		173,153,804
Net assets at August 31, 2024		\$284,834,768

Financial statements (continued)

Statement of assets and liabilities at August 31, 2024 (continued)

(dollars and shares in thousands, except per-share amounts)

Shares of beneficial interest issued and outstanding (no stated par value) – unlimited shares authorized (3,798,153 total shares outstanding)

		Shares	Net asset value
	Net assets	outstanding	per share
Class A	\$143,792,623	1,907,864	\$75.37
Class C	3,748,286	57,398	65.30
Class T	16	_*	75.37
Class F-1	6,323,149	84,653	74.69
Class F-2	38,784,556	515,804	75.19
Class F-3	13,537,790	179,278	75.51
Class 529-A	14,380,051	193,949	74.14
Class 529-C	343,239	5,248	65.40
Class 529-E	400,888	5,507	72.80
Class 529-T	27	_*	75.34
Class 529-F-1	15	_*	73.97
Class 529-F-2	1,316,105	17,473	75.32
Class 529-F-3	203	3	75.25
Class R-1	320,923	4,807	66.76
Class R-2	2,307,050	34,036	67.78
Class R-2E	262,681	3,628	72.39
Class R-3	4,999,298	68,554	72.92
Class R-4	5,002,745	67,176	74.47
Class R-5E	1,379,035	18,515	74.48
Class R-5	2,790,896	36,994	75.44
Class R-6	45,145,192	597,266	75.59

^{*}Amount less than one thousand.

Financial statements (continued)

Statement of operations for the year ended August 31, 2024

Income: Income: Dividends (net of non-U.S. taxes of \$42,927; also includes \$755,809 from affiliates)			(dollars in thousands)
Dividends (net of non-U.S. taxes of \$42,927; also includes \$755,800 from affiliates)	Investment income:		
Also includes \$755,809 from affiliates) \$2,585,816 Interest from unaffiliated issuers 5,541 \$5,541	Income:		
Interest from unaffiliated issuers 5,541 Securities lending income (net of fees) 1,438 \$ 2,592,795 Fees and expenses*:	Dividends (net of non-U.S. taxes of \$42,927;		
Securities lending income (net of fees) 1,438 \$ 2,592,795 Fees and expenses*:		\$ 2,585,816	
Fees and expenses*:		•	
Investment advisory services		1,438	\$ 2,592,795
Distribution services 451,879 Transfer agent services 178,525 Administrative services 77,232 529 plan services 8,423 Reports to shareholders 4,425 Registration statement and prospectus 2,681 Trustees' compensation 2,212 Auditing and legal 475 Custodian 307 Other 307 Net investment income 1,201,093 Net realized gain (loss) and unrealized appreciation (depreciation): Unaffiliated issuers Unaffiliated issuers 20,261,644 Affiliated issuers 20,261,644 Affiliated issuers 454,156 Currency transactions 454,156 Currency transactions (depreciation) on: (4,582) 20,665,695 Net unrealized appreciation (depreciation) on: (45,82) 20,665,695 Investments (net of non-U.S. taxes of \$3,180): 42,794,669 42,794,669 Unaffiliated issuers 3,449,483 42,794,669 Affiliated issuers 3,449,483 42,6244,509	Fees and expenses*:		
Transfer agent services 178,525 Administrative services 77,232 529 plan services 8,423 Reports to shareholders 4,425 Registration statement and prospectus 2,681 Trustees' compensation 2,212 Auditing and legal 475 Custodian 3,185 Other 307 1,391,702 Net investment income 307 1,201,093 Net realized gain (loss) and unrealized appreciation (depreciation): Investments (net of non-U.S. taxes of \$3,204): 20,261,644 Affiliated issuers (45,523) In-kind redemptions 454,156 Currency transactions (4,582) 20,665,695 Net unrealized appreciation (depreciation) on: 1 1 Investments (net of non-U.S. taxes of \$3,180): 42,794,669 44,794,669 Affiliated issuers 3,449,483 42,794,669 Affiliated issuers 3,449,483 40,244,509 Net realized gain (loss) and unrealized appreciation (depreciation) 66,910,204	Investment advisory services	•	
Administrative services 77,232 529 plan services 8,423 Reports to shareholders 4,425 Registration statement and prospectus 2,681 Trustees' compensation 2,212 Auditing and legal 475 Custodian 3,185 Other 307 1,391,702 Net investment income 307 1,201,093 Net realized gain (loss) and unrealized appreciation (depreciation): Net realized gain (loss) and unrealized appreciation (depreciation): 20,261,644 Affiliated issuers (45,523) In-visit ind redemptions 454,156 Currency transactions (45,523) Net unrealized appreciation (depreciation) on: (45,822) 20,665,695 Net unrealized appreciation (depreciation) on: 42,794,669 44,794,669 46,244,509 Affiliated issuers 3,449,483 46,244,509 Affiliated issuers 3,449,483 46,244,509 Net realized gain (loss) and unrealized appreciation (depreciation) 66,910,204		451,879	
529 plan services 8,423 Reports to shareholders 4,425 Registration statement and prospectus 2,681 Trustees' compensation 2,212 Auditing and legal 475 Custodian 3,185 Other 307 1,391,702 Net investment income 1,201,093 Net realized gain (loss) and unrealized appreciation (depreciation): Net realized gain (loss) on: 20,261,644 Investments (net of non-U.S. taxes of \$3,204): 20,261,644 Affiliated issuers 20,261,644 Affiliated issuers 454,156 Currency transactions 454,156 Currency transactions (4,582) 20,665,695 Net unrealized appreciation (depreciation) on: 42,794,669 46,244,509 Investments (net of non-U.S. taxes of \$3,180): 42,794,669 46,244,509 Affiliated issuers 3,449,483 46,244,509 Net realized gain (loss) and unrealized appreciation (depreciation) 66,910,204	Transfer agent services	178,525	
Reports to shareholders 4,425 Registration statement and prospectus 2,681 Trustees' compensation 2,212 Auditing and legal 475 Custodian 3,185 Other 307 1,391,702 Net investment income 1,201,093 Net realized gain (loss) and unrealized appreciation (depreciation): Net realized gain (loss) on: 20,261,644 Investments (net of non-U.S. taxes of \$3,204): 20,261,644 Affiliated issuers 20,261,644 Affiliated issuers 454,156 Currency transactions 454,156 Currency transactions (depreciation) on: 454,156 Investments (net of non-U.S. taxes of \$3,180): 42,794,669 Unaffiliated issuers 42,794,669 Affiliated issuers 3,449,483 Currency translations 357 46,244,509 Net realized gain (loss) and unrealized appreciation (depreciation) 66,910,204	Administrative services		
Registration statement and prospectus 2,681 Trustees' compensation 2,212 Auditing and legal 475 Custodian 3,185 Other 307 1,391,702 Net investment income 1,201,093 Net realized gain (loss) and unrealized appreciation (depreciation): Net realized gain (loss) on: 20,261,644 Unaffiliated issuers 20,261,644 Affiliated issuers (45,523) In-kind redemptions 454,156 Currency transactions (4,582) 20,665,695 Net unrealized appreciation (depreciation) on: 1 Investments (net of non-U.S. taxes of \$3,180): 42,794,669 45,244,509 Affiliated issuers 42,794,669 44,6244,509 Affiliated issuers 3,449,483 46,244,509 Net realized gain (loss) and unrealized appreciation (depreciation) 66,910,204		· · · · · · · · · · · · · · · · · · ·	
Trustees' compensation 2,212 Auditing and legal 475 Custodian 3,185 Other 307 1,391,702 Net investment income 1,201,093 Net realized gain (loss) and unrealized appreciation (depreciation): Investments (net of non-U.S. taxes of \$3,204): Unaffiliated issuers 20,261,644 Affiliated issuers (45,523) In-kind redemptions 454,156 Currency transactions (4,582) 20,665,695 Net unrealized appreciation (depreciation) on: 1 Investments (net of non-U.S. taxes of \$3,180): 42,794,669 45,244,509 Affiliated issuers 42,794,669 3,449,483 Currency translations 357 46,244,509 Net realized gain (loss) and unrealized appreciation (depreciation) 66,910,204	Reports to shareholders	4,425	
Auditing and legal 475 Custodian 3,185 Other 307 1,391,702 Net investment income 1,201,093 Net realized gain (loss) and unrealized appreciation (depreciation): Net realized gain (loss) and unrealized appreciation (depreciation): Investments (net of non-U.S. taxes of \$3,204): 20,261,644 Unaffiliated issuers (45,523) In-kind redemptions 454,156 Currency transactions (4,582) 20,665,695 Net unrealized appreciation (depreciation) on: Investments (net of non-U.S. taxes of \$3,180): 42,794,669 46,244,509 Affiliated issuers 42,794,669 46,244,509 Affiliated issuers 3,449,483 46,244,509 Net realized gain (loss) and unrealized appreciation (depreciation) 66,910,204			
Custodian Other 3,185 307 1,391,702 Net investment income 1,201,093 Net realized gain (loss) and unrealized appreciation (depreciation): Net realized gain (loss) on: Investments (net of non-U.S. taxes of \$3,204): Unaffiliated issuers 20,261,644 Affiliated issuers (45,523) In-kind redemptions 454,156 Currency transactions (4,582) 20,665,695 Net unrealized appreciation (depreciation) on: 1nvestments (net of non-U.S. taxes of \$3,180): 42,794,669 42,794,669 Affiliated issuers 42,794,669 3,449,483 Currency translations 357 46,244,509 Net realized gain (loss) and unrealized appreciation (depreciation) 66,910,204		· · · · · · · · · · · · · · · · · · ·	
Other 307 1,391,702 Net investment income 1,201,093 Net realized gain (loss) and unrealized appreciation (depreciation): Net realized gain (loss) on: Investments (net of non-U.S. taxes of \$3,204): 20,261,644 Affiliated issuers 20,261,644 Affiliated issuers 454,156 Currency transactions 454,156 Currency transaction (depreciation) on: 454,156 Investments (net of non-U.S. taxes of \$3,180): 42,794,669 Affiliated issuers 42,794,669 Affiliated issuers 3,449,483 Currency translations 357 46,244,509 Net realized gain (loss) and unrealized appreciation (depreciation) 66,910,204		475	
Net investment income Net realized gain (loss) and unrealized appreciation (depreciation): Net realized gain (loss) on: Investments (net of non-U.S. taxes of \$3,204): Unaffiliated issuers Affiliated issuers In-kind redemptions Currency transactions Net unrealized appreciation (depreciation) on: Investments (net of non-U.S. taxes of \$3,180): Unaffiliated issuers Affiliated issuers Affiliated issuers Investments (net of non-U.S. taxes of \$3,180): Unaffiliated issuers Affiliated issuers A		3,185	
Net realized gain (loss) and unrealized appreciation (depreciation): Net realized gain (loss) on: Investments (net of non-U.S. taxes of \$3,204): Unaffiliated issuers Affiliated issuers (45,523) In-kind redemptions Currency transactions Net unrealized appreciation (depreciation) on: Investments (net of non-U.S. taxes of \$3,180): Unaffiliated issuers Affiliated issuers Affiliated issuers Currency translations Affiliated issuers Affiliated appreciation (depreciation) on: Unaffiliated issuers Affiliated issuers	Other	307	1,391,702
Net realized gain (loss) on: Investments (net of non-U.S. taxes of \$3,204): Unaffiliated issuers Affiliated issuers In-kind redemptions Unaffiliated appreciation (depreciation) on: Investments (net of non-U.S. taxes of \$3,180): Unaffiliated issuers Unaffiliated issuers Affiliated issuers Affiliated issuers Affiliated issuers Affiliated jasuers Affiliated issuers Affiliated jasuers Affiliated issuers Affiliated jasuers Affiliate	Net investment income		1,201,093
Investments (net of non-U.S. taxes of \$3,204): Unaffiliated issuers Affiliated issuers In-kind redemptions Currency transactions Net unrealized appreciation (depreciation) on: Investments (net of non-U.S. taxes of \$3,180): Unaffiliated issuers Affiliated issuers Affiliated issuers Affiliated issuers Currency translations Net realized gain (loss) and unrealized appreciation (depreciation) Net realized gain (loss) and unrealized appreciation (depreciation) 20,261,644 44,523) 454,156 (4,582) 20,665,695 42,794,669 3,449,483 42,794,669 357 46,244,509			
Unaffiliated issuers Affiliated issuers (45,523) In-kind redemptions Affiliated issuers (45,523) In-kind redemptions Affiliated issuers (45,523) Affiliated issuers (4,582) Affiliated issuers Affiliated i			
Affiliated issuers In-kind redemptions Currency transactions Net unrealized appreciation (depreciation) on: Investments (net of non-U.S. taxes of \$3,180): Unaffiliated issuers Affiliated issuers Affiliated issuers Currency translations Net realized gain (loss) and unrealized appreciation (depreciation) (45,523) 454,156 (4,582) 20,665,695 42,794,669 42,794,669 3,449,483 Currency translations 357 46,244,509		00.074.744	
In-kind redemptions 454,156 Currency transactions (4,582) 20,665,695 Net unrealized appreciation (depreciation) on: Investments (net of non-U.S. taxes of \$3,180): Unaffiliated issuers 42,794,669 Affiliated issuers 3,449,483 Currency translations 357 Net realized gain (loss) and unrealized appreciation (depreciation) Net realized gain (loss) and unrealized appreciation (depreciation)			
Currency transactions (4,582) 20,665,695 Net unrealized appreciation (depreciation) on: Investments (net of non-U.S. taxes of \$3,180): Unaffiliated issuers 42,794,669 Affiliated issuers 3,449,483 Currency translations 357 46,244,509 Net realized gain (loss) and unrealized appreciation (depreciation) 66,910,204			
Net unrealized appreciation (depreciation) on: Investments (net of non-U.S. taxes of \$3,180): Unaffiliated issuers Affiliated issuers 3,449,483 Currency translations Net realized gain (loss) and unrealized appreciation (depreciation) 42,794,669 3,449,483 46,244,509 66,910,204		•	00 //5 /05
Investments (net of non-U.S. taxes of \$3,180): Unaffiliated issuers Affiliated issuers Currency translations Net realized gain (loss) and unrealized appreciation (depreciation) 42,794,669 3,449,483 46,244,509 66,910,204		(4,582)	20,665,695
Unaffiliated issuers 42,794,669 Affiliated issuers 3,449,483 Currency translations 357 46,244,509 Net realized gain (loss) and unrealized appreciation (depreciation) 66,910,204			
Affiliated issuers Currency translations Net realized gain (loss) and unrealized appreciation (depreciation) 3,449,483 46,244,509 66,910,204		40.704.770	
Currency translations 357 46,244,509 Net realized gain (loss) and unrealized appreciation (depreciation) 66,910,204			
Net realized gain (loss) and unrealized appreciation (depreciation) 66,910,204			4/ 044 500
<u> </u>	•	35/	
Net increase (decrease) in net assets resulting from operations \$68,111,297	Net realized gain (loss) and unrealized appreciation (depreciation)		66,910,204
	Net increase (decrease) in net assets resulting from operations		\$68,111,297

^{*}Additional information related to class-specific fees and expenses is included in the notes to financial statements.

Statements of changes in net assets

(dollars in thousands)

	Year ended August 31,	
	2024	2023
Operations:		
Net investment income	\$ 1,201,093	\$ 1,463,436
Net realized gain (loss)	20,665,695	15,592,246
Net unrealized appreciation (depreciation)	46,244,509	18,725,785
Net increase (decrease) in net assets resulting from operations	68,111,297	35,781,467
Distributions paid to shareholders	(17,584,352)	(7,845,242)
Net capital share transactions	(1,018,212)	(5,638,235)
Total increase (decrease) in net assets	49,508,733	22,297,990
Net assets:		
Beginning of year	235,326,035	213,028,045
End of year	\$284,834,768	\$235,326,035

Notes to financial statements

1. Organization

The Growth Fund of America (the "fund") is registered under the Investment Company Act of 1940, as amended (the "1940 Act"), as an open-end, diversified management investment company. The fund seeks to provide growth of capital.

The fund has 21 share classes consisting of six retail share classes (Classes A, C, T, F-1, F-2 and F-3), seven 529 college savings plan share classes (Classes 529-A, 529-C, 529-E, 529-T, 529-F-1, 529-F-2 and 529-F-3) and eight retirement plan share classes (Classes R-1, R-2, R-2E, R-3, R-4, R-5E, R-5 and R-6). The 529 college savings plan share classes can be used to save for college education. The retirement plan share classes are generally offered only through eligible employer-sponsored retirement plans. The fund's share classes are described further in the following table:

Share class	Initial sales charge	Contingent deferred sales charge upon redemption	Conversion feature
Classes A and 529-A	Up to 5.75% for Class A; up to 3.50% for Class 529-A	None (except 1.00% for certain redemptions within 18 months of purchase without an initial sales charge)	None
Classes C and 529-C	None	1.00% for redemptions within one year of purchase	Class C converts to Class A after eight years and Class 529-C converts to Class 529-A after five years
Class 529-E	None	None	None
Classes T and 529-T*	Up to 2.50%	None	None
Classes F-1, F-2, F-3, 529-F-1, 529-F-2 and 529-F-3	None	None	None
Classes R-1, R-2, R-2E, R-3, R-4, R-5E, R-5 and R-6	None	None	None

^{*}Class T and 529-T shares are not available for purchase.

Holders of all share classes have equal pro rata rights to the assets, dividends and liquidation proceeds of the fund. Each share class has identical voting rights, except for the exclusive right to vote on matters affecting only its class. Share classes have different fees and expenses ("class-specific fees and expenses"), primarily due to different arrangements for distribution, transfer agent and administrative services. Differences in class-specific fees and expenses will result in differences in net investment income and, therefore, the payment of different per-share dividends by each share class.

2. Significant accounting policies

The fund is an investment company that applies the accounting and reporting guidance issued in Topic 946 by the U.S. Financial Accounting Standards Board. The fund's financial statements have been prepared to comply with U.S. generally accepted accounting principles ("U.S. GAAP"). These principles require the fund's investment adviser to make estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates. Subsequent events, if any, have been evaluated through the date of issuance in the preparation of the financial statements. The fund follows the significant accounting policies described in this section, as well as the valuation policies described in the next section on valuation.

Security transactions and related investment income – Security transactions are recorded by the fund as of the date the trades are executed with brokers. Realized gains and losses from security transactions are determined based on the specific identified cost of the securities. In the event a security is purchased with a delayed payment date, the fund will segregate liquid assets sufficient to meet its payment obligations. Dividend income is recognized on the ex-dividend date and interest income is recognized on an accrual basis. Market discounts, premiums and original issue discounts on fixed-income securities are amortized daily over the expected life of the security.

Class allocations – Income, fees and expenses (other than class-specific fees and expenses), realized gains and losses and unrealized appreciation and depreciation are allocated daily among the various share classes based on their relative net assets. Class-specific fees and expenses, such as distribution, transfer agent and administrative services, are charged directly to the respective share class.

Distributions paid to shareholders - Income dividends and capital gain distributions are recorded on the ex-dividend date.

Currency translation – Assets and liabilities, including investment securities, denominated in currencies other than U.S. dollars are translated into U.S. dollars at the exchange rates supplied by one or more pricing vendors on the valuation date. Purchases and sales of investment securities and income and expenses are translated into U.S. dollars at the exchange rates on the dates of such transactions. The effects of changes in exchange rates on investment securities are included with the net realized gain or loss and net unrealized appreciation or depreciation on investments in the fund's statement of operations. The realized gain or loss and unrealized appreciation or depreciation resulting from all other transactions denominated in currencies other than U.S. dollars are disclosed separately.

In-kind redemptions – The fund normally redeems shares in cash; however, under certain conditions and circumstances, payment of the redemption price wholly or partly with portfolio securities or other fund assets may be permitted. A redemption of shares in-kind is based upon the closing value of the shares being redeemed as of the trade date. Realized gains or losses resulting from redemptions of shares in-kind are reflected separately in the fund's statement of operations.

3. Valuation

Capital Research and Management Company ("CRMC"), the fund's investment adviser, values the fund's investments at fair value as defined by U.S. GAAP. The net asset value per share is calculated once daily as of the close of regular trading on the New York Stock Exchange, normally 4 p.m. New York time, each day the New York Stock Exchange is open.

Methods and inputs – The fund's investment adviser uses the following methods and inputs to establish the fair value of the fund's assets and liabilities. Use of particular methods and inputs may vary over time based on availability and relevance as market and economic conditions evolve.

Equity securities, including depositary receipts, are generally valued at the official closing price of, or the last reported sale price on, the exchange or market on which such securities are traded, as of the close of business on the day the securities are being valued or, lacking any sales, at the last available bid price. Prices for each security are taken from the principal exchange or market on which the security trades.

Fixed-income securities, including short-term securities, are generally valued at evaluated prices obtained from third-party pricing vendors. Vendors value such securities based on one or more of the inputs described in the following table. The table provides examples of inputs that are commonly relevant for valuing particular classes of fixed-income securities in which the fund is authorized to invest. However, these classifications are not exclusive, and any of the inputs may be used to value any other class of fixed-income security.

Fixed-income class	Examples of standard inputs
All	Benchmark yields, transactions, bids, offers, quotations from dealers and trading systems, new issues, spreads and other relationships observed in the markets among comparable securities; and proprietary pricing models such as yield measures calculated using factors such as cash flows, financial or collateral performance and other reference data (collectively referred to as "standard inputs")
Corporate bonds, notes & loans; convertible securities	Standard inputs and underlying equity of the issuer
Bonds & notes of governments & government agencies	Standard inputs and interest rate volatilities
Mortgage-backed; asset-backed obligations	Standard inputs and cash flows, prepayment information, default rates, delinquency and loss assumptions, collateral characteristics, credit enhancements and specific deal information

Securities with both fixed-income and equity characteristics, or equity securities traded principally among fixed-income dealers, are generally valued in the manner described for either equity or fixed-income securities, depending on which method is deemed most appropriate by the fund's investment adviser. The Capital Group Central Cash Fund ("CCF"), a fund within the Capital Group Central Fund Series ("Central Funds"), is valued based upon a floating net asset value, which fluctuates with changes in the value of CCF's portfolio securities. The underlying securities are valued based on the policies and procedures in CCF's statement of additional information.

Securities and other assets for which representative market quotations are not readily available or are considered unreliable by the fund's investment adviser are fair valued as determined in good faith under fair valuation guidelines adopted by the fund's investment adviser and approved by the board of trustees as further described. The investment adviser follows fair valuation guidelines, consistent with U.S. Securities and Exchange Commission rules and guidance, to consider relevant principles and factors when making fair value determinations. The investment adviser considers relevant indications of value that are reasonably and timely available to it in determining the fair value to be assigned to a particular security, such as the type and cost of the security, restrictions on resale of the security, relevant financial or business developments of the issuer, actively traded similar or related securities, dealer or broker quotes, conversion or exchange rights on the security, related corporate actions, significant events occurring after the close of trading in the security, and changes in overall market conditions. In addition, the closing prices of equity securities that trade in markets outside U.S. time zones may be adjusted to reflect significant events that occur after the close of local trading but before the net asset value of each share class of the fund is determined. Fair valuations of investments that are not actively trading involve judgment and may differ materially from valuations that would have been used had greater market activity occurred.

Processes and structure – The fund's board of trustees has designated the fund's investment adviser to make fair value determinations, subject to board oversight. The investment adviser has established a Joint Fair Valuation Committee (the "Committee") to administer, implement and oversee the fair valuation process and to make fair value decisions. The Committee regularly reviews its own fair value decisions, as well as decisions made under its standing instructions to the investment adviser's valuation team. The Committee reviews changes in fair value measurements from period to period, pricing vendor information and market data, and may, as deemed appropriate, update the fair valuation guidelines to better reflect the results of back testing and address new or evolving issues. Pricing decisions, processes and controls over security valuation are also subject to additional internal reviews facilitated by the investment adviser's global risk management group. The Committee reports changes to the fair valuation guidelines to the board of trustees. The fund's board and audit committee also regularly review reports that describe fair value determinations and methods.

Classifications – The fund's investment adviser classifies the fund's assets and liabilities into three levels based on the inputs used to value the assets or liabilities. Level 1 values are based on quoted prices in active markets for identical securities. Level 2 values are based on significant observable market inputs, such as quoted prices for similar securities and quoted prices in inactive markets. Certain securities trading outside the U.S. may transfer between Level 1 and Level 2 due to valuation adjustments resulting from significant market movements following the close of local trading. Level 3 values are based on significant unobservable inputs that reflect the investment adviser's determination of assumptions that market participants might reasonably use in valuing the securities. The valuation levels are not necessarily an indication of the risk or liquidity associated with the underlying investment. For example, U.S. government securities are reflected as Level 2 because the inputs used to determine fair value may not always be quoted prices in an active market. The following table presents the fund's valuation levels as of August 31, 2024 (dollars in thousands):

		Investment s	securities	
	Level 1	Level 2	Level 3	Total
Assets:				
Common stocks:				
Information technology	\$ 68,089,132	\$ 5,231,156	\$ 31,745	\$ 73,352,033
Consumer discretionary	39,297,000	2,444,935	_	41,741,935
Health care	39,570,203	1,839,673	70,327	41,480,203
Communication services	35,668,306	853,790	50,549	36,572,645
Industrials	31,933,259	2,180,839	7,728	34,121,826
Financials	24,324,921	507,432	_	24,832,353
Energy	7,633,201	_	_	7,633,201
Materials	5,436,697	665,373	_	6,102,070
Consumer staples	4,665,675	818,019	_	5,483,694
Utilities	2,141,808	_	_	2,141,808
Real estate	582,177	_	_	582,177
Preferred securities	465,389	_	481,767	947,156
Rights & warrants	_	_	_*	_,
Short-term securities	10,067,681			10,067,681
Total	\$269,875,449	\$14,541,217	\$642,116	\$285,058,782

^{*}Amount less than one thousand.

4. Risk factors

Investing in the fund may involve certain risks including, but not limited to, those described below.

Market conditions – The prices of, and the income generated by, the common stocks and other securities held by the fund may decline – sometimes rapidly or unpredictably – due to various factors, including events or conditions affecting the general economy or particular industries or companies; overall market changes; local, regional or global political, social or economic instability; governmental, governmental agency or central bank responses to economic conditions; changes in inflation rates; and currency exchange rate, interest rate and commodity price fluctuations.

Economies and financial markets throughout the world are highly interconnected. Economic, financial or political events, trading and tariff arrangements, wars, terrorism, cybersecurity events, natural disasters, public health emergencies (such as the spread of infectious disease), bank failures and other circumstances in one country or region, including actions taken by governmental or quasi-governmental authorities in response to any of the foregoing, could have impacts on global economies or markets. As a result, whether or not the fund invests in securities of issuers located in or with significant exposure to the countries affected, the value and liquidity of the fund's investments may be negatively affected by developments in other countries and regions.

Issuer risks – The prices of, and the income generated by, securities held by the fund may decline in response to various factors directly related to the issuers of such securities, including reduced demand for an issuer's goods or services, poor management performance, major litigation, investigations or other controversies related to the issuer, changes in the issuer's financial condition or credit rating, changes in government regulations affecting the issuer or its competitive environment and strategic initiatives such as mergers, acquisitions or dispositions and the market response to any such initiatives. An individual security may also be affected by factors relating to the industry or sector of the issuer or the securities markets as a whole, and conversely an industry or sector or the securities markets may be affected by a change in financial condition or other event affecting a single issuer.

Investing in growth-oriented stocks – Growth-oriented common stocks and other equity-type securities (such as preferred stocks, convertible preferred stocks and convertible bonds) may involve larger price swings and greater potential for loss than other types of investments.

Investing outside the U.S. - Securities of issuers domiciled outside the U.S. or with significant operations or revenues outside the U.S., and securities tied economically to countries outside the U.S., may lose value because of adverse political, social, economic or market developments (including social instability, regional conflicts, terrorism and war) in the countries or regions in which the issuers are domiciled, operate or generate revenue or to which the securities are tied economically. These securities may also lose value due to changes in foreign currency exchange rates against the U.S. dollar and/or currencies of other countries. Issuers of these securities may be more susceptible to actions of foreign governments, such as nationalization, currency blockage or the imposition of price controls, sanctions, or punitive taxes, each of which could adversely impact the value of these securities. Securities markets in certain countries may be more volatile and/or less liquid than those in the U.S. Investments outside the U.S. may also be subject to different regulatory, legal, accounting, auditing, financial reporting and recordkeeping requirements, and may be more difficult to value, than those in the U.S. In addition, the value of investments outside the U.S. may be reduced by foreign taxes, including foreign withholding taxes on interest and dividends. Further, there may be increased risks of delayed settlement of securities purchased or sold by the fund, which could impact the liquidity of the fund's portfolio. The risks of investing outside the U.S. may be heightened in connection with investments in emerging markets.

Management – The investment adviser to the fund actively manages the fund's investments. Consequently, the fund is subject to the risk that the methods and analyses, including models, tools and data, employed by the investment adviser in this process may be flawed or incorrect and may not produce the desired results. This could cause the fund to lose value or its investment results to lag relevant benchmarks or other funds with similar objectives.

5. Certain investment techniques

Securities lending – The fund has entered into securities lending transactions in which the fund earns income by lending investment securities to brokers, dealers or other institutions. Each transaction involves three parties: the fund, acting as the lender of the securities, a borrower, and a lending agent that acts as an intermediary.

Securities lending transactions are entered into by the fund under a securities lending agent agreement with the lending agent. The lending agent facilitates the exchange of securities between the fund and approved borrowers, ensures that securities loans are properly coordinated and documented, marks-to-market the value of collateral daily, secures additional collateral from a borrower if it falls below preset terms, and may reinvest cash collateral on behalf of the fund according to agreed parameters. The lending agent provides indemnification to the fund against losses resulting from a borrower default. Although risk is mitigated by the collateral and indemnification, the fund could experience a delay in recovering its securities and a potential loss of income or value if a borrower fails to return securities, collateral investments decline in value or the lending agent fails to perform.

The borrower is required to post highly liquid assets, such as cash or U.S. government securities, as collateral for the loan in an amount at least equal to the value of the securities loaned. Investments made with cash collateral are recognized as assets in the fund's investment portfolio. The same amount is recorded as a liability in the fund's statement of assets and liabilities. While securities are on loan, the fund will continue to receive the equivalent of the interest, dividends or other distributions paid by the issuer, as well as a portion of the interest on the investment of the collateral. Additionally, although the fund does not have the right to vote on securities while they are on loan, the fund has a right to consent on corporate actions and a right to recall loaned securities to vote. A borrower is obligated to return loaned securities at the conclusion of a loan or, during the pendency of a loan, on demand from the fund.

As of August 31, 2024, the total value of securities on loan was \$242,201,000, and the total value of collateral received was \$256,014,000, which consisted entirely of cash. Investment securities purchased from cash collateral are disclosed in the fund's investment portfolio as short-term securities. Securities received as collateral, if any, are not recognized as fund assets. The contractual maturity of cash collateral received under the securities lending agreement is classified as overnight and continuous.

6. Taxation and distributions

Federal income taxation – The fund complies with the requirements under Subchapter M of the Internal Revenue Code applicable to regulated investment companies and intends to distribute substantially all of its net taxable income and net capital gains each year. The fund is not subject to income taxes to the extent such distributions are made. Therefore, no federal income tax provision is required.

As of and during the year ended August 31, 2024, the fund did not have a liability for any unrecognized tax benefits. The fund recognizes interest and penalties, if any, related to unrecognized tax benefits as income tax expense in the statement of operations. During the year, the fund did not incur any significant interest or penalties.

The fund's tax returns are generally not subject to examination by federal, state and, if applicable, non-U.S. tax authorities after the expiration of each jurisdiction's statute of limitations, which is typically three years after the date of filing but can be extended in certain iurisdictions.

Non-U.S. taxation – Dividend and interest income are recorded net of non-U.S. taxes paid. The fund may file withholding tax reclaims in certain jurisdictions to recover a portion of amounts previously withheld. As a result of rulings from European courts, the fund filed for additional reclaims related to prior years ("EU reclaims"). These reclaims are recorded when the amount is known and there are no significant uncertainties on collectability. During the year ended August 31, 2024, the fund recognized \$166,000 in EU reclaims (net of \$34,000 in fees and the effect of realized gain or loss from currency translations) and \$98,000 in interest related to European court rulings, which is included in dividend income and interest income, respectively, in the fund's statement of operations. Gains realized by the fund on the sale of securities in certain countries, if any, may be subject to non-U.S. taxes. The fund generally records an estimated deferred tax liability based on unrealized gains to provide for potential non-U.S. taxes payable upon the sale of these securities.

Distributions – Distributions determined on a tax basis may differ from net investment income and net realized gains for financial reporting purposes. These differences are due primarily to different treatment for items such as currency gains and losses; short-term capital gains and losses; capital losses related to sales of certain securities within 30 days of purchase; unrealized appreciation of certain investments in securities outside the U.S. and cost of investments sold. The fiscal year in which amounts are distributed may differ from the year in which the net investment income and net realized gains are recorded by the fund for financial reporting purposes. The fund may also designate a portion of the amount paid to redeeming shareholders as a distribution for tax purposes.

During the year ended August 31, 2024, the fund reclassified \$1,203,097,000 from total distributable earnings to capital paid in on shares of beneficial interest to align financial reporting with tax reporting.

As of August 31, 2024, the tax basis components of distributable earnings, unrealized appreciation (depreciation) and cost of investments were as follows (dollars in thousands):

Undistributed ordinary income Undistributed long-term capital gains	\$ 1,049,937 17,508,725
Gross unrealized appreciation on investments	157,788,768
Gross unrealized depreciation on investments	(3,182,959)
Net unrealized appreciation (depreciation) on investments	154,605,809
Cost of investments	130,452,973

Distributions paid were characterized for tax purposes as follows (dollars in thousands):

	Yea	r ended August 31,	2024	Year ended August 31, 2023					
Share class	Ordinary income	Long-term capital gains	Total distributions paid	Ordinary income	Long-term capital gains	Total distributions paid			
Class A	\$ 683,157	\$ 7,940,924	\$ 8,624,081	\$307,380	\$3,429,760	\$3,737,140			
Class C	_	249,484	249,484	2	117,785	117,787			
Class T	_*	1	1	_*	_*	_:			
Class F-1	29,257	370,402	399,659	12,410	173,346	185,756			
Class F-2	253,465	2,156,455	2,409,920	143,132	909,282	1,052,414			
Class F-3	96,454	733,988	830,442	61,984	318,394	380,378			
Class 529-A	66,100	811,383	877,483	29,180	354,906	384,086			
Class 529-C	_	23,919	23,919	_*	12,044	12,044			
Class 529-E	1,154	23,521	24,675	59	10,547	10,606			
Class 529-T	_*	1	1	_*	1	1			
Class 529-F-1	_*	1	1	_*	_*				
Class 529-F-2	7,997	66,449	74,446	4,285	26,021	30,306			
Class 529-F-3	_*	2	2	_*	1	1			
Class R-1	_	20,837	20,837	_	9,831	9,831			
Class R-2	_	144,914	144,914	_	64,186	64,186			
Class R-2E	408	15,372	15,780	_	6,495	6,495			
Class R-3	12,906	297,617	310,523	_	137,213	137,213			
Class R-4	22,522	295,691	318,213	12,048	165,279	177,327			
Class R-5E	8,961	80,465	89,426	4,958	34,260	39,218			
Class R-5	20,366	160,135	180,501	8,080	46,013	54,093			
Class R-6	347,025	2,643,019	2,990,044	235,139	1,211,221	1,446,360			
Total	\$1,549,772	\$16,034,580	\$17,584,352	\$818,657	\$7,026,585	\$7,845,242			

^{*}Amount less than one thousand.

7. Fees and transactions with related parties

CRMC, the fund's investment adviser, is the parent company of Capital Client Group, Inc. ("CCG"), the principal underwriter of the fund's shares, and American Funds Service Company® ("AFS"), the fund's transfer agent. CRMC, CCG and AFS are considered related parties to the fund.

Investment advisory services – The fund has an investment advisory and service agreement with CRMC that provides for monthly fees accrued daily. These fees are based on a series of decreasing annual rates beginning with 0.500% on the first \$1 billion of daily net assets and decreasing to 0.225% on such assets in excess of \$341 billion. For the year ended August 31, 2024, the investment advisory services fees were \$662,358,000, which were equivalent to an annualized rate of 0.257% of average daily net assets.

Class-specific fees and expenses – Expenses that are specific to individual share classes are accrued directly to the respective share class. The principal class-specific fees and expenses are further described below:

Distribution services – The fund has plans of distribution for all share classes, except Class F-2, F-3, 529-F-2, 529-F-3, R-5E, R-5 and R-6 shares. Under the plans, the board of trustees approves certain categories of expenses that are used to finance activities primarily intended to sell fund shares and service existing accounts. The plans provide for payments, based on an annualized percentage of average daily net assets, ranging from 0.25% to 1.00% as noted in this section. In some cases, the board of trustees has limited the amounts that may be paid to less than the maximum allowed by the plans. All share classes with a plan may use up to 0.25% of average daily net assets to pay service fees, or to compensate CCG for paying service fees, to firms that have entered into agreements with CCG to provide certain shareholder services. The remaining amounts available to be paid under each plan are paid to dealers to compensate them for their sales activities.

Share class	Currently approved limits	Plan limits		
Class A	0.25%	0.25%		
Class 529-A	0.25	0.50		
Classes C, 529-C and R-1	1.00	1.00		
Class R-2	0.75	1.00		
Class R-2E	0.60	0.85		
Classes 529-E and R-3	0.50	0.75		
Classes T, F-1, 529-T, 529-F-1 and R-4	0.25	0.50		

For Class A and 529-A shares, distribution-related expenses include the reimbursement of dealer and wholesaler commissions paid by CCG for certain shares sold without a sales charge. These share classes reimburse CCG for amounts billed within the prior 15 months but only to the extent that the overall annual expense limits are not exceeded. As of August 31, 2024, there were no unreimbursed expenses subject to reimbursement for Class A or 529-A shares.

Transfer agent services – The fund has a shareholder services agreement with AFS under which the fund compensates AFS for providing transfer agent services to each of the fund's share classes. These services include recordkeeping, shareholder communications and transaction processing. Under this agreement, the fund also pays sub-transfer agency fees to AFS. These fees are paid by AFS to third parties for performing transfer agent services on behalf of fund shareholders.

Administrative services – The fund has an administrative services agreement with CRMC under which the fund compensates CRMC for providing administrative services to all share classes. Administrative services are provided by CRMC and its affiliates to help assist third parties providing non-distribution services to fund shareholders. These services include providing in-depth information on the fund and market developments that impact fund investments. Administrative services also include, but are not limited to, coordinating, monitoring and overseeing third parties that provide services to fund shareholders. The agreement provides the fund the ability to charge an administrative services fee at the annual rate of 0.05% of the average daily net assets attributable to each share class of the fund. Currently the fund pays CRMC an administrative services fee at the annual rate of 0.03% of the average daily net assets attributable to each share class of the fund for CRMC's provision of administrative services.

529 plan services – Each 529 share class is subject to service fees to compensate the Commonwealth Savers Plan (formerly, Virginia529) for its oversight and administration of the CollegeAmerica 529 college savings plan. The fees are based on the combined net assets invested in Class 529 and ABLE shares of the American Funds. Class ABLE shares are offered on other American Funds by Commonwealth Savers Plan through ABLEAmerica®, a tax-advantaged savings program for individuals with disabilities. Commonwealth Savers Plan is not considered a related party to the fund.

The quarterly fees are based on a series of decreasing annual rates beginning with 0.09% on the first \$20 billion of the combined net assets invested in the American Funds and decreasing to 0.03% on such assets in excess of \$75 billion. The fees for any given calendar quarter are accrued and calculated on the basis of the average net assets of Class 529 and ABLE shares of the American Funds for the last month of the prior calendar quarter. For the year ended August 31, 2024, the 529 plan services fees were \$8,423,000, which were equivalent to 0.057% of the average daily net assets of each 529 share class.

For the year ended August 31, 2024, class-specific expenses under the agreements were as follows (dollars in thousands):

Share class	Distribution services	Transfer agent services	Administrative services	529 plan services
Class A	\$313,271	\$ 98,548	\$38,711	Not applicable
Class C	34,672	2,670	1,048	Not applicable
Class T	_	_*	_*	Not applicable
Class F-1	14,410	7,213	1,758	Not applicable
Class F-2	Not applicable	36,643	10,398	Not applicable
Class F-3	Not applicable	155	3,591	Not applicable
Class 529-A	29,465	9,220	3,904	\$7,388
Class 529-C	3,274	240	100	190
Class 529-E	1,811	161	111	209
Class 529-T	_	_*	_*	_*
Class 529-F-1	_	_*	_*	_*
Class 529-F-2	Not applicable	546	336	636
Class 529-F-3	Not applicable	_*	_*	_*
Class R-1	2,971	274	90	Not applicable
Class R-2	15,859	7,186	634	Not applicable
Class R-2E	1,417	470	71	Not applicable
Class R-3	23,068	6,810	1,389	Not applicable
Class R-4	11,661	4,628	1,402	Not applicable
Class R-5E	Not applicable	1,919	386	Not applicable
Class R-5	Not applicable	1,292	778	Not applicable
Class R-6	Not applicable	550	12,525	Not applicable
Total class-specific expenses	\$451,879	\$178,525	\$77,232	\$8,423

^{*}Amount less than one thousand.

Trustees' deferred compensation – Trustees who are unaffiliated with CRMC may elect to defer the cash payment of part or all of their compensation. These deferred amounts, which remain as liabilities of the fund, are treated as if invested in shares of the fund or other American Funds. These amounts represent general, unsecured liabilities of the fund and vary according to the total returns of the selected funds. Trustees' compensation of \$2,212,000 in the fund's statement of operations reflects \$839,000 in current fees (either paid in cash or deferred) and a net increase of \$1,373,000 in the value of the deferred amounts.

Affiliated officers and trustees – Officers and certain trustees of the fund are or may be considered to be affiliated with CRMC, CCG and AFS. No affiliated officers or trustees received any compensation directly from the fund.

Investment in CCF – The fund holds shares of CCF, an institutional prime money market fund managed by CRMC. CCF invests in high-quality, short-term money market instruments. CCF is used as the primary investment vehicle for the fund's short-term instruments. CCF shares are only available for purchase by CRMC, its affiliates, and other funds managed by CRMC or its affiliates, and are not available to the public. CRMC does not receive an investment advisory services fee from CCF.

Security transactions with related funds – The fund purchased investment securities from, and sold investment securities to, other funds managed by CRMC (or funds managed by certain affiliates of CRMC) under procedures adopted by the fund's board of trustees. The funds involved in such transactions are considered related by virtue of having a common investment adviser (or affiliated investment advisers), common trustees and/or common officers. Each transaction was executed at the current market price of the security and no brokerage commissions or fees were paid in accordance with Rule 17a-7 of the 1940 Act. During the year ended August 31, 2024, the fund engaged in such purchase and sale transactions with related funds in the amounts of \$2,121,640,000 and \$2,893,062,000, respectively, which generated \$477,039,000 of net realized gains from such sales.

Interfund lending – Pursuant to an exemptive order issued by the SEC, the fund, along with other CRMC-managed funds (or funds managed by certain affiliates of CRMC), may participate in an interfund lending program. The program provides an alternate credit facility that permits the funds to lend or borrow cash for temporary purposes directly to or from one another, subject to the conditions of the exemptive order. The fund did not lend or borrow cash through the interfund lending program at any time during the year ended August 31, 2024.

8. Indemnifications

The fund's organizational documents provide board members and officers with indemnification against certain liabilities or expenses in connection with the performance of their duties to the fund. In the normal course of business, the fund may also enter into contracts that provide general indemnifications. The fund's maximum exposure under these arrangements is unknown since it is dependent on future claims that may be made against the fund. The risk of material loss from such claims is considered remote. Insurance policies are also available to the fund's board members and officers.

9. Capital share transactions

Capital share transactions in the fund were as follows (dollars and shares in thousands):

	Sales	;*	Reinvestm distribut		Repurcha	ases*	Net increase (decrease)		
Share class	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Shares	
Year ended August 31,	2024								
Class A	\$ 7,574,584	112,787	\$ 8,492,324	136,467	\$(14,063,129)	(209,455)	\$ 2,003,779	39,799	
Class C	513,180	8,773	248,697	4,588	(964,227)	(16,485)	(202,350)	(3,124)	
Class T	_	_	_	_	_	_	_	_	
Class F-1	157,402	2,365	395,444	6,409	(932,538)	(14,206)	(379,692)	(5,432)	
Class F-2	6,203,949	92,924	2,341,056	37,759	(7,713,236)	(114,954)	831,769	15,729	
Class F-3	2,109,975	31,288	814,669	13,096	(2,570,099)	(38,487)	354,545	5,897	
Class 529-A	1,249,932	18,874	,874 877,113 14,322		(1,989,733)	(29,865)	137,312	3,331	
Class 529-C	71,844	1,232	23,914	440	(138,681)	(2,362)	(42,923)	(690)	
Class 529-E	33,603	518	24,672	410	(64,453)	(985)	(6,178)	(57)	
Class 529-T	_	_	2	_+	_	_	2	_+	
Class 529-F-1	_	_	1	_†	_	_	1	_+	
Class 529-F-2	242,948	3,603	74,427	1,198	(164,806)	(2,418)	152,569	2,383	
Class 529-F-3	147	2	3	_†	_	_	150	2	
Class R-1	41,135	691	20,789	375	(77,173)	(1,288)	(15,249)	(222)	
Class R-2	350,154	5,787	144,778	2,573	(528,285)	(8,724)	(33,353)	(364)	
Class R-2E	50,167	785	15,780	263	(63,954)	(995)	1,993	53	
Class R-3	618,890	9,525	309,549	5,128	(1,134,684)	(17,476)	(206,245)	(2,823)	
Class R-4	525,539	7,912	317,919	5,169	(1,104,247)	(16,549)	(260,789)	(3,468)	
Class R-5E	291,639	4,326	89,409	1,455	(427,115)	(6,266)	(46,067)	(485)	
Class R-5	334,223	5,015	179,859	2,893	(637,948)	(9,493)	(123,866)	(1,585)	
Class R-6	3,370,256	50,205	2,977,264	47,812	(9,531,140)	(144,086)	(3,183,620)	(46,069)	
Total net increase									
(decrease)	\$23,739,567	356,612	\$17,347,669 	280,357	\$(42,105,448) ===================================	(634,094)	\$(1,018,212) ===================================	2,875	

	Sales	*	Reinvestm distribut		Repurcha	ases*	Net increase (decrease)		
Share class	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Shares	
Year ended August 31,	2023								
Class A	\$ 5,725,386	103,577	\$3,678,194	73,549	\$(11,399,414)	(208,515)	\$(1,995,834)	(31,389)	
Class C	395,297	8,137	117,298	2,662	(821,682)	(17,004)	(309,087)	(6,205)	
Class T	_	_	_	_	_	_	_	_	
Class F-1	153,056	2,807	183,315	3,695	(760,638)	(13,965)	(424,267)	(7,463)	
Class F-2	4,403,320	80,038	1,021,834	20,506	(6,522,635)	(119,804)	(1,097,481)	(19,260)	
Class F-3	2,538,667			7,464	(2,360,222)	(42,461)	551,532	11,799	
Class 529-A	882,036			7,793	(1,521,961)	(27,595)	(255,959)	(3,636)	
Class 529-C	61,040	1,257	12,037	273	(124,227)	(2,543)	(51,150)	(1,013)	
Class 529-E	27,482	509	10,604	219	(53,189)	(981)	(15,103)	(253)	
Class 529-T	_	_	1	_†	_	_	1	_+	
Class 529-F-1	_	_	_†	_+	_	_	_†	_†	
Class 529-F-2	153,664	2,779	30,299	607	(129,292)	(2,326)	54,671	1,060	
Class 529-F-3	_	_	1	_†	_	_	1	_†	
Class R-1	32,457	655	9,819	218	(63,237)	(1,264)	(20,961)	(391)	
Class R-2	304,034	6,049	64,127	1,405	(443,328)	(8,868)	(75,167)	(1,414)	
Class R-2E	31,358	594	6,493	134	(38,209)	(717)	(358)	11	
Class R-3	529,977	9,848	136,794	2,813	(976,948)	(18, 252)	(310,177)	(5,591)	
Class R-4	448,671	8,189	177,216	3,584	(1,983,581)	(34,628)	(1,357,694)	(22,855)	
Class R-5E	201,997	3,748	39,212	794	(207,623)	(3,811)	33,586	731	
Class R-5	1,081,748	17,761	53,737	1,076	(365,230)	(6,659)	770,255	12,178	
Class R-6	3,706,018	68,610	1,440,755	28,798	(6,281,816)	(112,663)	(1,135,043)	(15,255)	
Total net increase (decrease)	\$20,676,208	377,520	\$7,738,789	155,590	\$(34,053,232)	(622,056)	\$(5,638,235)	(88,946)	

^{*}Includes exchanges between share classes of the fund.

10. Investment transactions

The fund engaged in purchases and sales of investment securities, excluding short-term securities and U.S. government obligations, if any, of \$61,869,635,000 and \$76,910,869,000, respectively, during the year ended August 31, 2024.

[†]Amount less than one thousand.

Financial highlights

	1	ncome (loss)	from investmen	t operations ¹	Divid	ends and distril	outions						
Net a: valu begini Year ended of ye	e, ning	Net investment income (loss)	Net gains (losses) on securities (both realized and unrealized)	Total from investment operations	Dividends (from net investment income)	Distributions (from capital gains)	Total dividends and distributions	Net asset value, end of year	Total return ^{2,3}	Net assets, end of year (in millions)	Ratio of expenses to average net assets before reimburse- ments ⁴	Ratio of expenses to average net assets after reimburse- ments ^{3,4}	Ratio of net income (loss) to average net assets ³
Class A:													
8/31/2024 \$62.	30	\$.27	\$ 17.47	\$ 17.74	\$(.37)	\$(4.30)	\$(4.67)	\$75.37	30.05%	\$143,793	.61%	.61%	.39%
8/31/2023 55.	10	.34	8.87	9.21	(.17)	(1.84)	(2.01)	62.30	17.60	116,384	.63	.63	.61
8/31/2022 78.	42	.15	(17.40)	(17.25)	(.06)	(6.01)	(6.07)	55.10	(23.78)	104,664	.60	.60	.23
8/31/2021 63.	18	.05	18.10	18.15	(.17)	(2.74)	(2.91)	78.42	29.49	144,012	.61	.61	.07
8/31/2020 49.	39	.22	17.23	17.45	(.38)	(3.28)	(3.66)	63.18	37.07	114,585	.64	.64	.42
Class C:													
8/31/2024 54.	60	(.21)	15.21	15.00	-	(4.30)	(4.30)	65.30	29.09	3,748	1.36	1.36	(.35)
8/31/2023 48.	73	(.07)	7.78	7.71	_5	(1.84)	(1.84)	54.60	16.72	3,305	1.38	1.38	(.14)
8/31/2022 70.	50	(.32)	(15.44)	(15.76)	-	(6.01)	(6.01)	48.73	(24.36)	3,252	1.36	1.36	(.53)
8/31/2021 57.	32	(.42)	16.34	15.92	_	(2.74)	(2.74)	70.50	28.54	4,852	1.35	1.35	(.68)
8/31/2020 45.	09	(.14)	15.65	15.51	_5	(3.28)	(3.28)	57.32	36.07	4,153	1.38	1.38	(.30)
Class T:													
8/31/2024 62.	31	.44	17.46	17.90	(.54)	(4.30)	(4.84)	75.37	30.39 ⁶	_7	.356	.356	.66 ⁶
8/31/2023 55.	13	.49	8.85	9.34	(.32)	(1.84)	(2.16)	62.31	17.92 ⁶	_7		.36 ⁶	.886
8/31/2022 78.	44	.31	(17.38)	(17.07)	(.23)	(6.01)	(6.24)	55.13	$(23.58)^6$	_7	.00	.36 ⁶	.476
8/31/2021 63.	19	.20	18.10	18.30	(.31)	(2.74)	(3.05)	78.44	29.76 ⁶	_7		.38 ⁶	.296
8/31/2020 49.	39	.34	17.24	17.58	(.50)	(3.28)	(3.78)	63.19	37.40 ⁶	_7	.406	.406	.666
Class F-1:													
8/31/2024 61.	78	.23	17.32	17.55	(.34)	(4.30)	(4.64)	74.69	29.98	6,323	.66	.66	.35
8/31/2023 54.	64	.32	8.79	9.11	(.13)	(1.84)	(1.97)	61.78	17.57	5,566	.66	.66	.58
8/31/2022 77.	79	.11	(17.25)	(17.14)	-	(6.01)	(6.01)	54.64	(23.82)	5,330	.66	.66	.16
8/31/2021 62.	70	.01	17.95	17.96	(.13)	(2.74)	(2.87)	77.79	29.40	7,747	.66	.66	.02
8/31/2020 49.	02	.20	17.11	17.31	(.35)	(3.28)	(3.63)	62.70	37.05	8,196	.67	.67	.40
Class F-2:													
8/31/2024 62.	17	.41	17.42	17.83	(.51)	(4.30)	(4.81)	75.19	30.32	38,785	.40	.40	.61
8/31/2023 55.	00	.46	8.84	9.30	(.29)	(1.84)	(2.13)	62.17	17.87	31,088	.41	.41	.84
8/31/2022 78.	29	.29	(17.35)	(17.06)	(.22)	(6.01)	(6.23)	55.00	(23.62)	28,563	.40	.40	.43
8/31/2021 63.	07	.19	18.07	18.26	(.30)	(2.74)	(3.04)	78.29	29.76	37,459	.40	.40	.28
8/31/2020 49.	30	.34	17.20	17.54	(.49)	(3.28)	(3.77)	63.07	37.38	28,682	.41	.41	.65
Class F-3:													
8/31/2024 62.		.48	17.49	17.97	(.57)	(4.30)	(4.87)	75.51	30.46	13,538	.29	.29	.71
8/31/2023 55.	22	.52	8.87	9.39	(.36)	(1.84)	(2.20)	62.41	17.99	10,820	.30	.30	.94
8/31/2022 78.	57	.36	(17.40)	(17.04)	(.30)	(6.01)	(6.31)	55.22	(23.53)	8,922	.29	.29	.54
8/31/2021 63.	28	.26	18.13	18.39	(.36)	(2.74)	(3.10)	78.57	29.88	11,555	.30	.30	.38
8/31/2020 49.	45	.39	17.26	17.65	(.54)	(3.28)	(3.82)	63.28	37.53	8,120	.31	.31	.75
Class 529-A:													
8/31/2024 61.	36	.24	17.19	17.43	(.35)	(4.30)	(4.65)	74.14	30.00	14,380	.65	.65	.36
8/31/2023 54.	31	.31	8.73	9.04	(.15)	(1.84)	(1.99)	61.36	17.55	11,697	.67	.67	.58
8/31/2022 77.	37	.13	(17.14)	(17.01)	(.04)	(6.01)	(6.05)	54.31	(23.79)	10,549	.64	.64	.20
8/31/2021 62.	38	.02	17.87	17.89	(.16)	(2.74)	(2.90)	77.37	29.45	14,481	.64	.64	.03
8/31/2020 48.	80	.20	17.01	17.21	(.35)	(3.28)	(3.63)	62.38	37.01	11,695	.68	.68	.38

Financial highlights (continued)

		Income (loss) from investment operations ¹			Divid	Dividends and distributions							
Year ended	Net asset value, beginning of year	Net investment income (loss)	Net gains (losses) on securities (both realized and unrealized)	Total from investment operations	Dividends (from net investment income)	Distributions (from capital gains)	Total dividends and distributions	Net asset value, end of year	Total return ^{2,3}	Net assets, end of year (in millions)	Ratio of expenses to average net assets before reimburse- ments ⁴	Ratio of expenses to average net assets after reimburse- ments ^{3,4}	Ratio of net income (loss) to average net assets ³
Class 529-C:													
8/31/2024	\$54.70	\$(.23)	\$ 15.23	\$ 15.00	\$ -	\$(4.30)	\$(4.30)	\$65.40	29.03%	\$ 343	1.40%	1.40%	(.39)%
8/31/2023	48.85	(.10)	7.79	7.69	_	(1.84)	(1.84)	54.70	16.64	325	1.44	1.44	(.20)
8/31/2022	70.68	(.35)	(15.47)	(15.82)	_	(6.01)	(6.01)	48.85	(24.39)	340	1.41	1.41	(.59)
8/31/2021	57.48	(.44)	16.38	15.94	_	(2.74)	(2.74)	70.68	28.49	561	1.38	1.38	(.71)
8/31/2020	45.23	(.15)	15.68	15.53	_	(3.28)	(3.28)	57.48	35.98	544	1.42	1.42	(.31)
Class 529-E:													
8/31/2024	60.33	.08	16.90	16.98	(.21)	(4.30)	(4.51)	72.80	29.72	401	.88	.88	.12
8/31/2023	53.41	.18	8.59	8.77	(.01)	(1.84)	(1.85)	60.33	17.26	335	.91	.91	.33
8/31/2022	76.33	(.04)	(16.87)	(16.91)	-	(6.01)	(6.01)	53.41	(23.98)	311	.88	.88	(.05)
8/31/2021	61.59	(.14)	17.64	17.50	(.02)	(2.74)	(2.76)	76.33	29.14	447	.88	.88	(.21)
8/31/2020	48.22	.08	16.80	16.88	(.23)	(3.28)	(3.51)	61.59	36.70	372	.90	.90	.16
Class 529-T:													
8/31/2024	62.29	.39	17.46	17.85	(.50)	(4.30)	(4.80)	75.34	30.30 ⁶	_7	.426	.426	.59 ⁶
8/31/2023	55.10	.46	8.86	9.32	(.29)	(1.84)	(2.13)	62.29	17.87 ⁶	_7	.41 ⁶	.41 ⁶	.83 ⁶
8/31/2022	78.41	.28	(17.39)	(17.11)	(.27)	(6.01)	(6.20)	55.10	(23.64) ⁶	_7	.416	.41 ⁶	.42 ⁶
8/31/2021	63.17	.16	18.10	18.26	(.28)	(2.74)	(3.02)	78.41	29.71 ⁶	_7	.41 .44 ⁶	.41 ⁶	.42 .24 ⁶
8/31/2020	49.38	.32	17.23	17.55	(.48)	(3.28)	(3.76)	63.17	37.33 ⁶	_7	.44 ⁶	.44 ⁶	.62 ⁶
Class 529-F-1:													
8/31/2024	61.23	.38	17.14	17.52	(.48)	(4.30)	(4.78)	73.97	30.28 ⁶	_7	.436	.436	.57 ⁶
8/31/2023	54.19	.42	8.71	9.13	(.25)	(1.84)	(2.09)	61.23	17.80 ⁶	_7	.46 ⁶	.46 ⁶	.77 ⁶
8/31/2022	77.23	.23	(17.09)	(16.86)	(.17)	(6.01)	(6.18)	54.19	(23.68) ⁶	_7	.486	.486	.35 ⁶
8/31/2021	62.24	.13	17.88	18.01	(.17)	(2.74)	(3.02)	77.23	29.74 ⁶	_7	.42 ⁶	.426	.22 ⁶
8/31/2020	48.69	.31	16.99	17.30	(.47)	(3.28)	(3.75)	62.24	37.35	642	.45	.45	.61
Class 529-F-2:													
8/31/2024	62.28	.41	17.45	17.86	(.52)	(4.30)	(4.82)	75.32	30.33	1,316	.40	.40	.60
8/31/2023	55.10	.47	8.85	9.32	(.30)	(1.84)	(2.14)	62.28	17.88	940	.38	.38	.86
8/31/2022	78.40	.29	(17.37)	(17.08)	(.21)	(6.01)	(6.22)	55.10	(23.61)	773	.40	.40	.44
8/31/2021 ^{8,9}	59.21	.15	22.06	22.21	(.28)	(2.74)	(3.02)	78.40	38.38 ¹⁰	932	.43 ¹¹	.43 ¹¹	.26 ¹¹
Class 529-F-3:													
8/31/2024	62.21	.39	17.48	17.87	(.53)	(4.30)	(4.83)	75.25	30.39	_7	.35	.35	.56
8/31/2023	55.05	.48	8.85	9.33	(.33)	(1.84)	(2.17)	62.21	17.93	_7	.36	.36	.88
8/31/2022	78.35	.32	(17.36)	(17.04)	(.25)	(6.01)	(6.26)	55.05	(23.58)	_7	.35	.35	.49
8/31/2021 ^{8,9}	59.21	.19	22.06	22.25	(.23)	(2.74)	(3.11)	78.35	38.45 ¹⁰	_7	.38 ¹¹	.35 ¹¹	.3211
Class R-1:													
8/31/2024	55.74	(.22)	15.54	15.32	_	(4.30)	(4.30)	66.76	29.06	321	1.38	1.38	(.37)
8/31/2023	49.71	(.22)	7.94	7.87	_	(1.84)	(1.84)	55.74	16.72	280	1.38	1.38	(.14)
8/31/2022	71.80	(.33)	(15.75)	(16.08)	_	(6.01)	(6.01)	49.71	(24.36)	269	1.38	1.38	(.55)
8/31/2021	58.35	(.45)	16.64	16.19	_	(2.74)	(2.74)	71.80	28.49	402	1.38	1.38	(.70)
8/31/2020	45.86	(.45)	15.93	15.77	_	(3.28)	(3.28)	58.35	36.01	388	1.30	1.30	(.70)
0/3//2020	45.00	(.10)	13.73	13.77		(3.20)	(3.20)	50.55	30.01	300	1.40	1.40	(.55)

Financial highlights (continued)

		Income (loss) from investment operations ¹		Divid	lends and distri	outions							
Year ended	Net asset value, beginning of year	Net investment income (loss)	Net gains (losses) on securities (both realized and unrealized)	Total from investment operations	Dividends (from net investment income)	Distributions (from capital gains)	Total dividends and distributions	Net asset value, end of year	Total return ^{2,3}	Net assets, end of year (in millions)	Ratio of expenses to average net assets before reimburse- ments ⁴	Ratio of expenses to average net assets after reimburse- ments ^{3,4}	Ratio of net income (loss) to average net assets ³
Class R-2: 8/31/2024 8/31/2023 8/31/2022 8/31/2021 8/31/2020	\$56.54 50.40 72.72 59.07 46.39	\$(.23) (.08) (.35) (.46) (.16)	\$ 15.77 8.06 (15.96) 16.85 16.12	\$ 15.54 7.98 (16.31) 16.39 15.96	\$ - - - -	\$(4.30) (1.84) (6.01) (2.74) (3.28)	\$(4.30) (1.84) (6.01) (2.74) (3.28)	\$67.78 56.54 50.40 72.72 59.07	29.05% 16.71 (24.37) 28.49 36.01	\$ 2,307 1,945 1,805 2,672 2,337	1.38% 1.39 1.40 1.39 1.40	1.38% 1.39 1.40 1.39 1.40	(.37)% (.15) (.57) (.71) (.34)
Class R-2E: 8/31/2024 8/31/2023 8/31/2022 8/31/2021 8/31/2020	60.05 53.25 76.28 61.67 48.30	(.05) .08 (.18) (.28) (.02)	16.80 8.56 (16.84) 17.63 16.83	16.75 8.64 (17.02) 17.35 16.81	(.11) - - - (.16)	(4.30) (1.84) (6.01) (2.74) (3.28)	(4.41) (1.84) (6.01) (2.74) (3.44)	72.39 60.05 53.25 76.28 61.67	29.43 17.06 (24.15) 28.85 36.44	263 215 190 291 252	1.09 1.10 1.10 1.09 1.11	1.09 1.10 1.10 1.09 1.11	(.08) .14 (.27) (.42) (.04)
Class R-3: 8/31/2024 8/31/2023 8/31/2022 8/31/2021 8/31/2020	60.44 53.51 76.50 61.75 48.32	.05 .16 (.08) (.18)	16.92 8.61 (16.90) 17.67 16.84	16.97 8.77 (16.98) 17.49 16.90	(.19) - - - (.19)	(4.30) (1.84) (6.01) (2.74) (3.28)	(4.49) (1.84) (6.01) (2.74) (3.47)	72.92 60.44 53.51 76.50 61.75	29.62 17.22 (24.02) 29.05 36.63	4,999 4,314 4,118 6,233 5,794	.94 .94 .94 .94	.94 .94 .94 .94	.07 .30 (.12) (.26) .12
Class R-4: 8/31/2024 8/31/2023 8/31/2022 8/31/2021 8/31/2020	61.59 54.47 77.58 62.53 48.89	.24 .32 .12 .02	17.27 8.77 (17.20) 17.92 17.06	17.51 9.09 (17.08) 17.94 17.27	(.33) (.13) (.02) (.15) (.35)	(4.30) (1.84) (6.01) (2.74) (3.28)	(4.63) (1.97) (6.03) (2.89) (3.63)	74.47 61.59 54.47 77.58 62.53	30.00 17.59 (23.81) 29.44 37.06	5,003 4,351 5,093 7,878 7,403	.64 .65 .64 .64	.64 .65 .64 .64	.37 .59 .18 .03
Class R-5E: 8/31/2024 8/31/2023 8/31/2022 8/31/2021 8/31/2020	61.62 54.53 77.70 62.61 48.97	.38 .43 .25 .16	17.26 8.77 (17.20) 17.94 17.09	17.64 9.20 (16.95) 18.10 17.40	(.48) (.27) (.21) (.27) (.48)	(4.30) (1.84) (6.01) (2.74) (3.28)	(4.78) (2.11) (6.22) (3.01) (3.76)	74.48 61.62 54.53 77.70 62.61	30.27 17.82 (23.66) 29.69 37.36	1,379 1,171 996 1,337 990	.44 .45 .45 .44	.44 .45 .45 .44	.57 .79 .39 .23
Class R-5: 8/31/2024 8/31/2023 8/31/2022 8/31/2021 8/31/2020	62.36 55.17 78.50 63.22 49.40	.45 .50 .32 .23	17.48 8.85 (17.39) 18.12 17.24	17.93 9.35 (17.07) 18.35 17.61	(.55) (.32) (.25) (.33) (.51)	(4.30) (1.84) (6.01) (2.74) (3.28)	(4.85) (2.16) (6.26) (3.07) (3.79)	75.44 62.36 55.17 78.50 63.22	30.41 17.93 (23.58) 29.84 37.48	2,791 2,406 1,457 2,322 2,716	.34 .35 .34 .34	.34 .35 .34 .34	.67 .90 .48 .34
Class R-6: 8/31/2024 8/31/2023 8/31/2022 8/31/2021 8/31/2020	62.46 55.26 78.63 63.32 49.48	.48 .52 .36 .27 .40	17.51 8.88 (17.42) 18.14 17.26	17.99 9.40 (17.06) 18.41 17.66	(.56) (.36) (.30) (.36) (.54)	(4.30) (1.84) (6.01) (2.74) (3.28)	(4.86) (2.20) (6.31) (3.10) (3.82)	75.59 62.46 55.26 78.63 63.32	30.48 17.99 (23.54) 29.90 37.53	45,145 40,184 36,396 46,741 38,573	.29 .30 .29 .29	.29 .30 .29 .29	.72 .94 .54 .38

Financial highlights (continued)

Year	anda	۸ h		c+ 3	21
rear	enae	an A	wan	ST .	SI.

	2024	2023	2022	2021	2020
Portfolio turnover rate for all share classes ¹²	25%	31%	30%	24%	28%

¹Based on average shares outstanding.

²Total returns exclude any applicable sales charges, including contingent deferred sales charges.

³This column reflects the impact, if any, of certain reimbursements from CRMC. During one of the years shown, CRMC reimbursed a portion of transfer agent services fees for Class 529-F-3 shares.

⁴Ratios do not include expenses of any Central Funds. The fund indirectly bears its proportionate share of the expenses of any Central Funds.

⁵Amount less than \$.01.

⁶All or a significant portion of assets in this class consisted of seed capital invested by CRMC and/or its affiliates. Fees for distribution services are not charged or accrued on these seed capital assets. If such fees were paid by the fund on seed capital assets, fund expenses would have been higher and net income and total return would have been lower.

⁷Amount less than \$1 million.

⁸Based on operations for a period that is less than a full year.

⁹Class 529-F-2 and 529-F-3 shares began investment operations on October 30, 2020.

¹⁰Not annualized.

¹¹Annualized.

 $^{^{12}}$ Rates do not include the fund's portfolio activity with respect to any Central Funds.

Report of Independent Registered Public Accounting Firm

To the shareholders and the Board of Trustees of The Growth Fund of America:

Opinion on the Financial Statements and Financial Highlights

We have audited the accompanying statement of assets and liabilities of The Growth Fund of America (the "Fund"), including the investment portfolio, as of August 31, 2024, the related statement of operations for the year then ended, the statements of changes in net assets for each of the two years in the period then ended, the financial highlights for each of the five years in the period then ended, and the related notes. In our opinion, the financial statements and financial highlights present fairly, in all material respects, the financial position of the Fund as of August 31, 2024, and the results of its operations for the year then ended, the changes in its net assets for each of the two years in the period then ended, and the financial highlights for each of the five years in the period then ended in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements and financial highlights are the responsibility of the Fund's management. Our responsibility is to express an opinion on the Fund's financial statements and financial highlights based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Fund in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and financial highlights are free of material misstatement, whether due to error or fraud. The Fund is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements and financial highlights, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements and financial highlights. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements and financial highlights. Our procedures included confirmation of securities owned as of August 31, 2024, by correspondence with the custodian and brokers; when replies were not received from brokers, we performed other auditing procedures. We believe that our audits provide a reasonable basis for our opinion.

/s/ Deloitte & Touche LLP

Costa Mesa, California October 14, 2024

We have served as the auditor of one or more American Funds investment companies since 1956.

We are required to advise you of the federal tax status of certain distributions received by shareholders during the fiscal year. The fund hereby designates the following amounts for the fund's fiscal year ended August 31, 2024:

Long-term capital gains	\$16,783,484,000
Qualified dividend income	100%
Corporate dividends received deduction	100%
U.S. government income that may be exempt from state taxation	\$111,837,000

Individual shareholders should refer to their Form 1099 or other tax information, which will be mailed in January 2025, to determine the calendar year amounts to be included on their 2024 tax returns. Shareholders should consult their tax advisors.

Changes in and disagreements with accountants

Not applicable

Matters submitted for shareholder vote

Not applicable

Remuneration paid to directors, officers and others

Refer to information in the financial statements.

Approval of Investment Advisory and Service Agreement

The fund's board has approved the continuation of the fund's Investment Advisory and Service Agreement (the "agreement") with Capital Research and Management Company ("CRMC") for an additional one-year term through November 30, 2025. The board approved the agreement following the recommendation of the fund's Contracts Committee (the "committee"), which is composed of all the fund's independent board members. The board and the committee determined in the exercise of their business judgment that the fund's advisory fee structure was fair and reasonable in relation to the services provided, and that approving the agreement was in the best interests of the fund and its shareholders.

In reaching this decision, the board and the committee took into account their interactions with CRMC and information furnished to them throughout the year and otherwise provided to them, as well as information prepared specifically in connection with their review of the agreement, and they were advised by their independent counsel with respect to the matters considered. They considered the following factors, among others, but did not identify any single issue or particular piece of information that, in isolation, was the controlling factor, and each board and committee member did not necessarily attribute the same weight to each factor.

1. Nature, extent and quality of services

The board and the committee considered the depth and quality of CRMC's investment management process, including its global research capabilities; the experience, capability and integrity of its senior management and other personnel; the low turnover rates of its key personnel; the overall financial strength and stability of CRMC and the Capital Group organization; the resources and systems CRMC devotes to investment management (the manner in which the fund's assets are managed, including liquidity management), financial, investment operations, compliance, trading, proxy voting, shareholder communications, and other services; and the ongoing evolution of CRMC's organizational structure designed to maintain and strengthen these qualities. The board and the committee also considered the nature, extent and quality of administrative and shareholder services provided by CRMC to the fund under the agreement and other agreements, as well as the benefits to fund shareholders from investing in a fund that is part of a large family of funds. The board and the committee considered the risks assumed by CRMC in providing services to the fund, including operational, business, financial, reputational, regulatory and litigation risks. The board and the committee concluded that the nature, extent and quality of the services provided by CRMC have benefited and should continue to benefit the fund and its shareholders.

2. Investment results

The board and the committee considered the investment results of the fund in light of its objective. They compared the fund's investment results with those of other funds (including funds that currently form the basis of the Lipper index for the category in which the fund is included) and data such as publicly disclosed benchmarks, including applicable market and fund indexes over various periods (including the fund's lifetime) through March 31, 2024. They generally placed greater emphasis on investment results over longer term periods and relative to benchmarks consistent with the fund's objective. On the basis of this evaluation and the board's and the committee's ongoing review of investment results, and considering the relative market conditions during certain reporting periods, the board and the committee concluded that the fund's investment results have been satisfactory for renewal of the agreement, and that CRMC's record in managing the fund indicated that its continued management should benefit the fund and its shareholders.

3. Advisory fees and total expenses

The board and the committee compared the advisory fees and total expense levels of the fund to those of other relevant funds. They observed that the fund's advisory fees and expenses generally compared favorably to those of other similar funds included in the comparable Lipper category. The board and the committee also considered the breakpoint discounts in the fund's advisory fee structure that reduce the level of fees charged by CRMC to the fund as fund assets increase. In addition, they reviewed information regarding the effective advisory fees charged to non-mutual fund clients by CRMC and its affiliates. They noted that, to the extent there were differences between the advisory fees paid by the fund and the advisory fees paid by those clients, the differences appropriately reflected the investment, operational, regulatory and market differences between advising the fund and the other clients. The board and the committee concluded that the fund's cost structure was fair and reasonable in relation to the services provided, as well as in relation to the risks assumed by the adviser in sponsoring and managing the fund, and that the fund's shareholders receive reasonable value in return for the advisory fees and other amounts paid to CRMC by the fund.

4. Ancillary benefits

The board and the committee considered a variety of other benefits that CRMC and its affiliates receive as a result of CRMC's relationship with the fund and other American Funds, including fees for administrative services provided to certain share classes; fees paid to CRMC's affiliated transfer agent; sales charges and distribution fees received and retained by the fund's principal underwriter, an affiliate of CRMC; and possible ancillary benefits to CRMC and its institutional management affiliates in managing other investment vehicles. The board and the committee reviewed CRMC's portfolio trading practices, noting that CRMC bears the cost of third-party research. The board and committee also noted that CRMC benefited from the use of commissions from portfolio transactions made on behalf of the fund to facilitate payment to certain broker-dealers for research to comply with regulatory requirements applicable to these firms, with all such amounts reimbursed by CRMC. The board and the committee took these ancillary benefits into account in evaluating the reasonableness of the advisory fees and other amounts paid to CRMC by the fund.

5. Adviser financial information

The board and the committee reviewed information regarding CRMC's costs of providing services to the American Funds, including personnel, systems and resources of investment, compliance, trading, accounting and other administrative operations. They considered CRMC's costs and related cost allocation methodology, as well as its track record of investing in technology, infrastructure and staff to maintain and expand services and capabilities, respond to industry and regulatory developments, and attract and retain qualified personnel. They noted information regarding the compensation structure for CRMC's investment professionals. They reviewed information on the profitability of the investment adviser and its affiliates. The board and the committee also compared CRMC's profitability and compensation data to the reported results and data of a number of large, publicly held investment management companies. The board and the committee noted the competitiveness and cyclicality of both the mutual fund industry and the capital markets, and the importance in that environment of CRMC's long-term profitability for maintaining its independence, company culture and management continuity. They further considered the breakpoint discounts in the fund's advisory fee structure and CRMC's sharing of potential economies of scale, or efficiencies, through breakpoints and other fee reductions and costs voluntarily absorbed. The board and the committee concluded that the fund's advisory fee structure reflected a reasonable sharing of benefits between CRMC and the fund's shareholders.